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ABSTRACT OF THE DISSERTATION
Identification of Multi-tissue Protein Quantitative Trait Loci and Causal Inference of Protein
Effects in Neurological and Other Complex Human Diseases via Mendelian Randomization
by
Chengran Yang
Doctor of Philosophy in Biology and Biomedical Sciences
Human and Statistical Genetics
Washington University in St. Louis, 2021
Professor Carlos Cruchaga, Chair

Alzheimer disease (AD) is the most common neurodegenerative disease, affecting 6.2 million
people mostly aged 65 years or older in the United States as of early 2021. AD has been widely
studied and characterized worldwide, but there is still no effective treatment or cure. Even the
latest FDA-approved treatment, Aducanumab, cannot stop decline or improve cognition. To
develop a truly effective treatments, researchers keep discovering genetic and molecular
mechanisms underlying the disease. Protein biomarkers are keys to bridge the mechanisms to
disease. Here, I first used a high-throughput proteomic dataset from three tissues (CSF, plasma,
and brain) with array-based genotype data to discover protein quantitative trait loci (pQTLs)
within each tissue. Next, I replicated most of these findings with publicly available single tissue
pQTL datasets. I identified over 10 independent, local pQTLs and pleiotropy regions. I
investigated the tissue-specificity and genetic colocalization of pQTLs with QTLs of other
molecular traits. Finally, I used Mendelian randomization to infer protein causal effects on
xii

neurological and other complex diseases. Taken together, these findings prioritized the proteins
that play important role in human disease pathogenesis and helped identify potential biomarkers
for AD or other human diseases.

xiii

Chapter 1: Background and overview
1.1 Background
There are three major sections in the Background chapter: Alzheimer disease, protein
quantitative trait locus, and Mendelian randomization. For Alzheimer disease, I briefly
summarized the history, its current and future prevalence, the latest progress in treatment as of
fall 2021, and its fluid-based biomarker related studies. For protein quantitative trait locus, I first
reviewed the large-scale genome-wide association studies using intermediate traits, including
both gene expression and protein level. I next introduced the aptamer-based proteomic profiling
platform as it was used by multiple large-scale proteomic genome-wide association studies to
date. Finally, I described the prior work by our lab using a smaller-scale proteomic datasets from
an antibody-based platform. For Mendelian randomization, I briefly introduced the components,
basic equation, and recent applications using pQTLs as instrument variables to infer protein
effects on diseases.

1.1.1 Alzheimer Disease
Alzheimer disease (AD) is the most common neurodegenerative disease, affecting 6.2 million
people mostly aged 65 years or older in the United States as of early 2021. Furthermore, the total
number of individuals with AD in 2050 is projected to be 12.7 million per Alzheimer
Association (https://www.alz.org/alzheimers-dementia/facts-figures). The disease is named after
the German psychiatrist Dr. Alois Alzheimer, as he diagnosed the first case of AD in 19061.
Through these 115 years, AD has been widely studied and characterized worldwide, but there is
1

still no effective treatment or cure. Even the most recent FDA-approved treatment, Aducanumab,
developed primarily by Biogen, can only slow progression (in a limited population) of Mild
Cognitive Impairment (MCI) due to AD in its earliest stage2. This treatment cannot stop decline
or improve cognition even with its highest dose, despite its effect on clearing Aβ3,4. Thus, no
drugs are currently effective for all patients, and no drugs can cure the disease. To develop more
effective treatments, researchers keep discovering novel genetic and molecular mechanisms
underlying the disease. Biomarkers are keys to bridge the mechanism to disease.
Aβ and tau are the two core biomarkers validated for AD status. In the cerebrospinal fluid
(CSF), Aβ levels are lower in AD cases, while the levels of tau are higher. For Aβ, there are
multiple forms depending on the number of amino acids. Aβ42, as one major form with 42
amino acids, is widely studied. Motter and colleagues5 conducted the first quantitative study on
CSF Aβ42. The researchers performed the enzyme-linked immunosorbent assay (ELISA)6 using
the antibody specifically targeting the protein. They discovered subjects with AD have a
significant decrease compared to neither nondemented controls nor neurological disease controls.
Moreover, a relative recent meta-analysis7 suggested the consistency of the decrease in CSF
Aβ42 in AD patients in all 131 studies (a total of 9,949 AD cases and 6,841 controls).
For tau, two forms of proteins are studied, total-tau (t-tau) and phosphorylated-tau (p-tau). Total
tau in CSF was first quantified by ELISA method using monoclonal antibodies in 19958.
Blennow and colleagues studied total tau with the monoclonal antibodies, AT120, HT7 and BT2,
by targeting all six isoforms of tau. Compared to controls, the researchers observed a significant
increase in t-tau in AD patients. This observation has been replicated in later studies, as
indicated by the meta-analysis on 151 studies from Olsson and colleagues7. Phosphorylated tau
has been studied as it is known that post-translational modification may play a role in tau
2

pathology. P-tau was first also quantified by ELISA method on specific monoclonal antibodies
(AT180, AT270, HT7 and AT120) by Blennow and colleagues8. This approach captured the
phosphorylated residues at threonine 181 (P-tau181) and 231 (P-tau231). The researchers
reported a significant higher level in p-tau in AD patients than controls. This study served as a
breakthrough9 as this increase in p-tau was only observed in AD patients, but not in other nonAD neurological diseases (e.g. frontal lobe dementia, vascular dementia, Parkinson disease).
Moreover, Olsson and colleagues7 meta-analyzed and found the consistency of the increase in
CSF p-tau in AD subjects existed in all 89 studies (a total of 7,498 AD cases and 5,126 controls).
T-tau or p-tau to Aβ42 ratio has been reported to have a higher sensitivity and specificity than
Aβ42, t-tau or p-tau alone9,10. Fagan and colleagues11 from our institution reported t-tau or p-tau
to Aβ42 ratio could predict AD status. Harari and colleagues12 from our NGI Center applied the
P-tau181 over Aβ42 ratio to discovering biomarkers of AD with proteome data generated by
Myriad Rules Based Medicine (RBM) platform. The authors highlighted this quantitative trait
can increase the power to identify novel biomarkers (e.g. H-FABP, heart-type fatty acid binding
protein) for AD.
Yet, these core biomarkers are insufficient to serve as the only biomarkers because AD cases are
pathophysiologically heterogeneous. Novel biomarkers are still needed to facilitate the disease
diagnosis. Several non-core CSF biomarkers thus have been reported in the last decade,
including Neurogranin13, Visinin-like protein 1 (VILIP-1)14, chitinase-3-like protein 1 (YKL40)15, and neurofilament light (NfL)16.
Due to the great accessibility of the samples, blood (serum or plasma) biomarkers are more likely
to be used for screening novel biomarkers17. However, the discovery for blood-based
3

biomarkers have been challenging due to the lack of shared proteins with brain, and the larger
variance between abundant and rare proteins. Thus, the replication of findings in blood
biomarkers was less successful than CSF biomarkers historically.
Besides the above biochemical fluid biomarkers, imaging biomarkers (derived from Magnetic
Resonance Imaging (MRI) or Positron Emission Tomography (PET)) have also been actively
developed in the AD community. However, these imaging biomarkers are beyond the scope of
this thesis.

1.1.2 Protein quantitative trait locus
Genome wide association studies (GWAS)18 have been applied to link genetic variants to
diseases. However, one caveat for GWAS findings is that most significant hits locate in the noncoding regions of genome, thus it is difficult to interpret the underlying functional mechanisms
with this link. Another caveat for GWA studies is the effect sizes for genetic association with
disease end point are mostly small, thus a successful GWAS require a large sample size (e.g.
over ten thousand)19, which is infeasible for a single laboratory to collect the participants. To
reveal the mechanisms of disease-associated genetic variants and to boost the power for
discovering more genetic variants given a moderate sample size, researchers have switched to
using intermediate traits instead.
Among genomic studies on intermediate molecular traits, gene expression measuring
transcription has widely been used to study the impact of a genetic mutation in large-scale
studies, such as Genotype-Tissue Expression (GTEx) project20,21. From its latest release (v8
dataset) in 2020, the researchers identified eQTLs with a total of 17,382 samples across 49
tissues or cell lines from 838 donors. In total, the scientists reported 23,268 genes with a cis4

eQTL (genetic variants located within 1 Mb of the target gene’s transcription start site (TSS))
and 143 genes with trans-eQTLs at a 5% gene-level false discovery rate (FDR).
Yet, protein quantitative trait locus (pQTL) studies have not been studied in such a large scale
across multiple tissues. Through the development of proteomic profiling technologies, largescaled blood-based pQTL studies have emerged in recent years22–25.
The first pQTL study was published in 200826. Borrowing the concept of “eQTL”, Melzer and
colleagues tested the hypothesis that “common genetic variation influences protein levels in a
human population”. Specifically, the authors evaluated 42 proteins measured in serum and
plasma from 1,200 individuals. The measurements of these proteins included ELISA
Immunoassay, Radio Immuno assay, and Chemiluminescent assay. In total, the researchers
identified eight cis-pQTLs (cis effects: variants in the gene encoding for the protein or within
300kb either side of that gene) and one trans-pQTL. The platforms for protein measurement were
heterogeneous in this study, but they opened the door of pQTL identification since then.
Several population-scale pQTL studies on blood-related samples have been published within last
four years (Table1.1). Ahola-Olli and colleagues22 identified pQTLs on 41 proteins with 8,293
individuals using the platform of Bio-Plex Pro Human Cytokine 27-plex Assay and 21-plex
Assay (Bio-Rad). Folkersen and colleagues23 studied 83 proteins with 3,394 subjects using the
platform of ProSeek CVD array I (Olink Biosciences). Suhre and colleagues24 conducted pQTL
analysis on 1,124 plasma proteins with 1,000 German subjects using SOMAscan platform
(SomaLogic). Researchers from INTERVAL study by Sun, Maranville, Peters et al25
investigated 3,622 plasma proteins using the customized SOMAscan platform with 3,622
participants. Emilsson, Ilkov, Lamb and colleagues27 explored 4,137 serum proteins using the
5

customized SOMAscan platform with 5,457 Icelanders. In late 2020, Folkersen, Gustafsson,
Wang and colleagues28 from SCALLOP consortium expanded their sample size to 30,931 after
three years of their original pQTL study. This approximately 10-fold increase led to 451 pQTLs
for 85 proteins out of the 90 cardiovascular centric proteins from the same OLINK platform.
Prior to the study of this thesis, there was only one study using CSF samples published (Table 1).
Sasayama and colleagues29 performed pQTL analysis on 1,126 proteins in 133 physically healthy
Japanese participants using SOMAscan platform (SomaLogic). The authors reported 421 cis and
25 trans pQTLs with FDR < 0.01. As the authors expected, these pQTL SNPs were more likely
to be disease/trait-associated variants identified by prior GWAS, compared to the enrichment of
non-pQTL SNPs with GWAS variants. Furthermore, Sasayama and colleagues reported several
pQTL shared between CSF and blood-related pQTLs.
Prior to the study of this thesis, there was one pQTL study profiled proteomics from the brain
tissues. Robins and colleagues30 constructed a cis-pQTL map for 7,376 proteins with 330
participants from ROS/MAP cohort. The authors used 6,526 proteins profiled from 149
participants of Banner Sun Health Brain and Body Donation Program cohort for replication.
Table1.1 Several representative published pQTL studies from 2017 to 2021
Studies
Sasayama et al 2017
PMID: 28031287

Ahola-Olli et al 2017
PMID: 27989323
Folkersen et al 2017
PMID: 28369058
Suhre et al 2017
PMID: 28240269

Number of
individuals

Number of
proteins

133

1,126

8293

41

3,394

83

1,000

1,124

Platform
SOMAscan
(SomaLogic)
Bio-Plex Pro Human
Cytokine
27-plex Assay and 21plex Assay (Bio-Rad)
Olink Proteomics
SOMAscan
(SomaLogic)

6

Sample type

CSF

Blood
Blood
Blood

Sun et al
(INTERVAL) 2018
PMID: 29875488
Emilsson et al 2018
PMID: 30072576
Folkersen et al 2020
PMID: 33067605
Robins et al 2021
PMID: 33571421

3,301

3,622

5,457

4,137

SOMAscan customized
by Cambridge University
SOMAscan customized
by Novartis

30,931

90

Olink Proteomics

Blood

330

7,376

Mass spectrometry

Brain

Blood
Blood

Observing these studies, the SOMAscan platform has expanded the high-throughput proteomic
profiling from less than 100 proteins to over 1,000 proteins per experiment in a population-scale.
This platform31 is based upon aptamer (SOMAmer, short for Slow Off-rate Modified Aptamer),
as it specifically binds to certain protein targets. The principle of multiplex SOMAmer affinitybased assay is described as the eight-step workflow below:
Step-1: Binding. SOMAmers and proteins within each sample are mixed in a 96-well
format (split into 3 chunks when applying to 3 dilution gradients for plasma; not split for
CSF and brain) microwell plates and allowed to bind. Cognate and non-cognate
SOMAmer-target protein complexes form in the binding phase. Free-floating SOMAmers
and proteins are also present at this stage.
Step-2: SOMAmer-protein binding. DNA-based SOMAmer molecules have unique
shapes selected to bind to a specific protein. SOMAmers contain biotin, a photocleavable linker, and a fluorescent tag at the end.
Step-3: Catch-1. SOMAmers are captured by a bead coated with streptavidin which
binds the biotin contained by each SOMAmer. Proteins not forming a complex would be
washed away.

7

Step-4: Proteins are tagged with NHS-biotin. The complexes are now labeled of beadassociated proteins with biotin under controlled conditions.
Step-5: Photocleavage and kinetic challenge. Ultraviolate light irradiation cleaves the
linker and SOMAmers are released from beads, leaving biotin, originally part of the
SOMAmer, on beads. Samples, diluted into a high concentration of dextran sulfate, are
challenged with this anionic competitor. Non-cognate complexes preferentially
dissociate.
Step-6: Catch-2. As of now, only the proteins now contain biotin, the SOMAmerprotein complexes are re-captured onto new avidin coated 2nd-set of beads by protein
biotin tag. Free SOMAmers are washed away after Catch-2 phase.
Step-7: Release. SOMAmers, remaining attached to beads, are released from complexes
into solution at high pH (under a denaturing condition).
Step-8: Quantification. Finally, remaining SOMAmers are relatively quantified by
hybridization to a standard microarray, containing specific single-stranded DNA probes
complementary to DNA sequence of the corresponding SOMAmer.
The binding interactions between aptamers and their protein targets are characterized by
several factors: 1) shape complementarity, 2) polar contacts, 3) hydrogen bonding
interactions, 4) charge-charge interactions. Its innovation also includes the measurement
of aptamer using microarray after washing off the bound proteins before quantification in
a microarray format.

8

However, none of the prior studies collected CSF or brain tissues in such a large cohort as serum
or plasma. Thus, a larger scale study on CSF or brain subjects will be extremely useful for the
scientific community studying AD and other neurological diseases.
Our lab has successfully studied the pQTLs in both plasma and CSF samples for AD patients and
controls. Using a multiplexed immunoassay from the RBM, Deming, Xia and colleagues32
reported 56 plasma pQTLs for 47 proteins using a panel of totally 146 proteins with 818
participants from a joint cohort of Alzheimer’s Disease Neuroimaging Initiative (ADNI) and
Washington University Knight Alzheimer Disease Research Center (Knight ADRC), in which 28
of these significant associations were novel. The authors also highlighted the pleiotropic effects,
defined as one genetic locus affecting multiple protein targets. Three genes (ABO, FUT2, APOE)
have been discovered with the pleiotropic effects. For CSF, Kauwe and colleagues33 reported 27
pQTLs for five proteins using a list of pre-selected 59 AD-related proteins from the RBM panel
with 574 participants from both ADNI and Knight ADRC. These five proteins were: 1)
Angiotensin-converting enzyme, 2) Chemokine (C-C motif) ligand 2, 3) Chemokine (C-C motif)
ligand 4, 4) Interleukin 6 receptor and 5) Matrix metalloproteinase-3; among which ACE, IL6R
and MMP3 were identified with cis-pQTLs, while CCL2 and CCL4 had trans-pQTLs.
Overall, studies on pQTLs highlighted the genetic controls of proteins, and could complement
with eQTL findings on explaining disease heritability. Design of a multi-tissue pQTL study
would fill the gap when comparing with multi-tissue eQTL findings.

1.1.3 Mendelian randomization
Causality between functions of intermediate traits and disease can be inferred by Mendelian
randomization (MR)34. MR was first invented in the economics, and later adapted by genetic
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epidemiologists to infer causality in the context of human genetics. MR generally has three key
components: 1) instrument, 2) exposure, 3) outcome. Confounders were hard to quantify, thus
epidemiologists claim environmental factors could be one of confounders. In the QTL
application, the instrumental variables (IVs) are the independent genetic variants after genetic
clumping by LD; the exposure is the molecular trait (gene expression or protein abundance)
associated with these genetic variants; the outcome is the disease or trait associated with these
genetic variants reported by prior population-scale GWAS.
There are three assumptions34,35 for choosing IVs: 1) The IV (Z) is associated with the exposure
X; 2) Z is independent of the confounding factors U that confound the association of exposure X
and the outcome Y; 3) Z is independent of outcome Y given exposure X and the confounding
factors U. For example, MR can be used to infer causal effect of protein CD33 (exposure) on AD
risk (outcome) given a pQTL of CD33.
To quantitatively estimate the causal effect of exposure X on outcome Y, researchers have
widely used a regression coefficient, termed as Wald estimator (or Wald ratio), for the simplest
case of linear association given one IV:

(1.1)

is the coefficient for the regression of outcome (Y) on the IV (Z), and is the coefficient for the
regression of exposure (X) on the IV (Z).
To further account for multiple IVs (three genotypes for a biallelic polymorphism), researchers
computed an estimator called two-stage least squares. For the first stage, a least-squares
regression of the exposure X on the IVs is performed. For the second stage, a least-squares
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regression of the outcome Y on the predicted values from the first regression is calculated. There
are several approaches to test the significance of the estimator. These approaches have been
implemented in R packages, such as MendelianRandomization36 and TwoSampleMR37.
In a recent study from Nature Medicine, Zhou and colleagues38 have successfully applied MR
reported plasma OAS1 protein was protective against Coronavirus Disease 2019 (COVID-19)
adverse outcome. The authors used the cis pQTL finding (rs4767027) of OAS1 from Sun et al
201825 to infer protein level affecting COVID-19 outcomes (severity, hospitalization,
susceptibility). A similar study from Nature Medicine performed by Gaziano and colleagues39
highlighted IFNAR2 and ACE2 proteins can also be targeted for treating COVID-19.
Moreover, there are studies using pQTLs in tissues different to plasma. One study40 used CSF
pQTLs from our lab inferred that soluble TREM2 reduced AD risk via pQTLs in MS4A gene
region. Another study41 used brain pQTLs from a mass-spectrometry-based platform30 inferred
12 proteins causally associated with seven neurological phenotypes (AD, amyotrophic lateral
sclerosis, depression, insomnia, intelligence, neuroticism, and schizophrenia).
With the advancement of disease GWAS curation from IEU open-GWAS project42, over
hundreds or even thousands of GWAS summary datasets can be directly downloaded for MR
usage. In 2020, Zheng and colleagues43 performed a phenome-wide study of two-sample MR
and colocalization on over 200 phenotypes (diseases/risk factors) using 1,002 proteins from five
large-scale plasma pQTL datasets mentioned above. A similar proteome-by-phenome-wide MR
study was performed by Bretherick and colleagues44 using 64 plasma pQTLs as instrumental
variables. These two studies extended the one protein on one disease MR framework (or limited
number of proteins on limited number of diseases) into the proteome by phenome scale.
11

1.2 Overview
The structure of this thesis is overviewed as follows: In Chapter 2, I reported the identification
of hundreds of pQTLs within each tissue of CSF, plasma, and brain. I further replicated most of
pQTLs with the publicly available tissue-matched pQTL lists. In Chapter 3, to identify
independent local pQTLs, I performed multiple rounds of conditional analyses on the primary
variants. Next, I detected tens of pleiotropy regions, depending on tissue, that associated with
two or more proteins. In Chapter 4, I investigated the tissue-specific pQTLs using two
statistical approaches (Multivariate Adaptive Shrinkage in R (MASHR) framework and overlap
between each tissue given different p-value thresholds). Moreover, to quantify the unique
genetic architecture of protein compared to other molecular traits, I performed colocalization of
pQTLs with xQTLs of expression, splicing, DNA-methylation, or histone-acetylation QTLs. In
Chapter 5, I first causally inferred protein effects on seven neurological traits using Mendelian
randomization. Next, to reposition drugs targeting proteins for these neurological traits, I queried
the proteins with significant MR results from the Drugbank database.

In Chapter 6, I extended

the MR framework to 211 human disease-related complex phenotypes, highlighting the
scalability to perform the first multi-tissue proteome-by-phenome-wide MR study. In Chapter
7, I summarized the thesis and pinpointed potential future directions.
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2.1 Introduction
Genome-wide association studies have been widely used to identify disease risk loci. However,
this framework has two limitations: 1) GWAS requires tens to hundreds of thousands of
participants; 2) Most GWAS loci locate in non-coding regions. Geneticists gradually used
intermediated traits to mitigate these limitations. Gene expression is the most popular molecular
trait as an intermediate trait to map GWAS signals. Large-scale population-wide eQTL studies
include eQTLgen45 from blood, metaBrain46 from brain, and GTEx21 from over 50 tissues.
However, eQTL mapping has not been able to fully identify the functional variants and genes
driving GWAS signals. One explanation is that many genetic variants alter protein levels without
affecting transcript levels25. Several published studies analyzed the genetic architecture of
protein levels, but most focused on a single tissue, mainly plasma23–25,32. A few studies with
smaller sample sizes reported CSF29,33 or brain tissue47. These studies suggest that a sizeable
proportion of pQTLs are not eQTLs and that additional GWAS signals can be mapped to protein
levels. Here, I used a high-throughput proteomic dataset from three tissues (CSF, plasma, and
brain) with array-based genotype data to discover pQTLs within each tissue. Moreover, I
replicated most these findings with publicly available single-tissue pQTL datasets.

2.2 Materials and methods
2.2.1 Aptamer-based proteomics data sample collection
This study included 1,537 participants from Washington University School of Medicine in St.
Louis. Samples from participants include three tissue types: CSF, plasma, and brain (parietal
lobe cortex). CSF samples were collected the morning after an overnight fast, processed, and
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stored at -80°C. Plasma samples were collected the morning after an overnight fast, immediately
centrifuged, and stored at -80°C. Brain tissues (~500mg) were collected from fresh frozen human
parietal lobes.
Table2.1 Demographics of the baseline cohort before QC
Total N

CSF
971

Plasma
636

Brain
458

Age [mean+/-sd]

69.0+/-9.3

70.4+/-9.8

82.2+/-12

Female/Male (%)
53%/47%/0%
56%/44%/0%
60%/40%/0%
Case/Control
249/717/5
230/401/5
297/27/134
CDR [>0/=0/unknown]
242/724/5
226/405/5
370/51/37
APOE e4 (%)
39%
42%
48%
Total N represents unique donors before QC; Age: For CSF, Age.at.LP is used; For plasma, Age.at.plasma.draw is
used; For brain, Age_at_last_assessment is used; Case/Control has three columns, as case, control, and other (for
CSF and plasma, 3rd column is unknown; for brain, 3rd column is a mix of other diseases and unknown status);
CDR (clinical dementia rating): For CSF, CDR.at.LP is used; For plasma, CDR_at_plasma.draw is used; For brain,
Final_CDR is used

For CSF tissue (Figure2.1a, Table2.1), there were 971 unique participants (including 249 AD
cases, 717 cognitively normal controls, and 5 with unknown status) and 1,300 samples (329
participants provided one baseline and one longitudinal sample) in total. Age is distributed with a
mean of 69.0 years and standard deviation of 9.3 years. 53% of the samples are from women.
For plasma tissue (Figure2.1a, Table2.1), there were 636 unique participants (including 230 AD
individuals, 401 cognitively normal controls and 5 with unknown status) and 648 samples in
total. Age is distributed with a mean of 70.4 years and standard deviation of 9.8 years. 56% of
the samples are from women.
For brain tissue (Figure2.1a, Table2.1), there were 458 unique participants (including 297 AD
cases, 27 cognitively normal controls and 134 with unknown or other status (e.g. FTD, other
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neurological diseases)) and 459 samples in total. Age is distributed with a mean of 82.2 years
and standard deviation of 12 years. 60% of the samples are from women.
The donor overlap across three tissues are shown as a Venn diagram in Figure2.1b: nine donors
were shared across all three tissues; 481 donors were shared by both CSF and plasma; 29 donors
were shared by plasma and brain; 481, 117 and 420 were exclusively for CSF, plasma, and brain,
respectively. The Venn Diagram was drawn using VennDiagram48 R package.
These recruited participants were evaluated by clinical personnel from Washington University.
AD severity was determined by the Clinical Dementia Rating (CDR)49 scale at the time of
lumbar puncture (LP, CSF samples) or blood draw (plasma).
For Brain samples, case–control status was determined by postmortem neuropathological
analysis of study participant brains based on CERAD50 and/or Khachaturian51 criteria. All AD
cases have a Braak stage of IV or higher and controls are III or lower. The neuropathological
diagnosis was performed studying several brain areas, not only parietal.
The Institutional Review Boards of Washington University School of Medicine in St. Louis
approved the study and research was carried out in accordance with the approved protocols.
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Figure2.1 Reproducibility of proteomic data. (a) Table of total sample size for each tissue before and after QC,
including the biological and technical replicates. (b) Venn diagram on the designed donor overlap across tissues. (c)
Scatterplot of 321 subjects with both longitudinal and baseline samples from CSF indicates a Pearson correlation
coefficient of 0.995 (95% confidence interval from 0.995 to 0.995). (d) Scatterplot of 11 subjects with both fasted
and nonfasted samples from plasma indicates a Pearson correlation coefficient of 0.907 (95% confidence interval
from 0.904 to 0.911). (e) Scatterplot of one subject with both longitudinal and baseline samples from plasma
indicates a Pearson correlation coefficient of 0.938 (95% confidence interval from 0.930 to 0.945). (f) Scatterplot of
one subject with two technical replicates from brain indicates a Pearson correlation coefficient of 0.976 (95%
confidence interval from 0.976 to 0.981).

2.2.2 Proteomic data QC process
A multiplexed, aptamer-based platform31 was used to measure the relative concentrations
(relative fluorescent units, RFU) of proteins from CSF, plasma, and brain tissues, using 1,305
modified aptamers in total. The assay covers a dynamic range of 108, and measures all three
major categories: secreted, membrane, and intracellular proteins (Figure2.2). The proteins cover
a wide range of molecular functions, such as protein binding and the MAPK cascade. The
coverage of proteins on the platform has taken into account proteins known to be relevant to
human disease, including neurodegenerative diseases52 and cardiovascular diseases53; thus it has
been widely used for biomarker discovery.
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Figure2.2 Bar-plots of the percentage of three protein categories within each tissue. Three categories of
proteins passing QC are annotated based on UniProt database. Intracellcular proteins are color coded in red;
membrane proteins are in green; secreated proteins are in blue.

Aliquots of 150 μl of tissue were sent to the Genome Technology Access Center at Washington
University in St. Louis for protein measurement. Assay details have been previously described
by Gold and colleagues31 from SomaLogic Inc. In brief, modified single-stranded DNA aptamers
are used to bind specific protein targets that are then quantified by a DNA microarray. Protein
concentrations are quantified as relative fluorescence units (RFU).
Quality control (QC) was performed at the sample and aptamer levels using control aptamers
(positive and negative controls) and calibrator samples. At the sample level, hybridization
controls on each plate were used to correct for systematic variability in hybridization. The
median signal over all aptamers was used to correct for within-run technical variability. This
median signal was assigned to different dilution sets within each tissue. For CSF samples, a 20%
dilution rate was used. For plasma samples, three different dilution sets (40%, 1%, and 0.005%)
were used. For brain samples, a 20% dilution rate was used.
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To QC the proteomics datasets (Figure2.3a-d), the protein/analyte outliers were first removed by
applying four criteria:
1) Minimum detection filtering. Limit of detection (LOD) was defined as the summation of
average expression level of the new NP-buffer (used as dilution buffer of CSF samples since
plate-42) and K fold of standard deviation (K = 2). If the analyte for a given sample was less
than the LOD, this sample was an outlier. Collectively, if the number of outliers given an
analyte was less than 15% of total sample size, the analyte was kept.
2) Flagging analytes based on the scale factor difference. The scale factor difference was
calculated as the absolute value of the maximum difference between the calibration scale
factor per aptamer and the median for each of the plates run. If the value for this analyte was
less than 0.5, the analyte passed this criterion (NOTE: SomaLogic SQS report used 0.4).
3) CV of calibrators lower than 0.15. The coefficient of variation (CV) for each aptamer was
calculated by dividing the standard deviation by the mean of each calibrator at the raw protein
level. If the analyte had a CV of less than 0.15, this analyte passed the CV QC.
4) Interquartile range (IQR) strategy. Outliers were identified if the subject was located
outside of either end of distribution using a 1.5-fold of IQR given the log10 transformation of
the protein level. Collectively, if the number of outliers given an analyte was greater than 15%
of total sample size (aka none-outliers given an analyte was fewer than 85% of total sample
size) this analyte was filtered. Analytes were kept after passing all the criteria above for the
downstream statistical analysis.
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5) An orthogonal approach was used to call subject outliers based on IQR. Collectively, if the
number of outliers given an analyte was greater than 15% of total number of analytes passed
QC (aka none-outliers given an analyte was fewer than 85% of total number of analytes
passed QC), this subject was labeled as an outlier. Furthermore, the analytes were removed if
shared by most (~80%) of the subject outliers. After this second removal of analytes, subject
outliers were called again. Outlier subjects were again removed.
Proteins were mapped to UniProt54 identifiers and Entrez gene symbols. Mapping to Ensembl
gene IDs and genomic positions (start and end coordinates) was performed using gencode v30
liftover to hg19/GRCh37.

21

Figure2.3 QC pipeline. QC on both proteins (a to c) and samples (d) were described as follows: (a) Flowchart of
CSF protein level QC, starting from 1305; after step-1, Limit Of Detection VS 2-StDeviation, 807 proteins were
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kept with a pass-rate >= 85%; after step-2, given Max Difference of Scale Factor < 0.5, 749 proteins were kept; after
step-3, given Coefficient of Variation (of calibrator) < 0.15 & step-4, given IQR, sum(outliers) < 85%, 746 proteins
were kept. After step-5, 713 proteins that shared by < 30 samples (shared by ~80% of the subject outliers) were
kept. (b) Flowchart of plasma protein level QC, starting from 1305; after step-1, Limit Of Detection VS 2StDeviation, 1301 proteins were kept with a pass-rate >= 85%; after step-2, given Max Difference of Scale Factor <
0.5, 956 proteins were kept; after step-3, given Coefficient of Variation (of calibrator) < 0.15 & step-4, given IQR,
sum(outliers) < 85%, 955 proteins were kept. After step-5, 931 proteins that shared by < 10 samples (shared by
~80% of the subject outliers) were kept. (c) Flowchart of brain protein level QC, starting from 1305; after step-1,
Limit Of Detection VS 2-StDeviation, 1109 proteins were kept with a pass-rate >= 85%; after step-2, given Max
Difference of Scale Factor < 0.5, 1107 proteins were kept; after step-3, given Coefficient of Variation (of calibrator)
< 0.15 & step-4, given IQR, sum(outliers) < 85%, 1106 proteins were kept. After step-5, 1079 proteins that shared
by < 21 samples (shared by ~80% of the subject outliers) were kept. (d) Table of sample size after each step of QC
in genotype and proteomics. Within each tissue (1st column), we profiled proteomics from 1300 CSF, 648 plasma
and 459 samples (2nd column). From unique donors in proteomics data (3rd column), we first kept donors with
genotyping array data (4th column). We next kept only the donors with a European ancestry after checking
principal components (5th column). Moreover, we kept donors that were not close with each other (PI_HAT < 0.05)
after checking identity by descent (6th column). Finally, the samples remained only passing both the genotype and
protein data QC (7th column).

2.2.3 Reproducibility investigation via comparisons between biological or
technical replicates
To measure the reproducibility of the aptamer-based platform, I compared the replicates for the
same subject given each tissue.
For plasma samples, we included 11 subjects with two measures, one as fasted and the other as
non-fasted. After QC, I kept 931 proteins in 633 samples. Out of these 633 samples, all 11
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subjects with two measures remained in the analysis. The overall Pearson’s correlation
coefficient between fasted and non-fasted samples is 0.907, with a 95% confidence interval from
0.904 to 0.911 (Figure2.1d).
For plasma samples, we included one subject with two biological replicates: one collected in
1997, the other in 2007. Both samples passed QC. The overall Pearson’s correlation coefficient
between these two biological replicates is 0.938, with a 95% confidence interval from 0.9299 to
0.9453 (Figure2.1e).
For brain samples, we included one subject with two technical replicates. After QC, I kept 1,079
proteins and 435 samples. Out of these 435 samples, only one replicate of the subject remained.
Thus, I compared two technical replicates using the values before QC across all 1,305 proteins.
The overall Pearson’s correlation coefficient between these two replicates is 0.976, with a 95%
confidence interval from 0.9762 to 0.9812 (Figure2.1f).
For CSF samples, we designed 329 subjects with two measures, one as baseline (LP date1) and
the other as longitudinal (LP date 2). After QC, I kept 713 proteins and 1,270 samples. Out of
these 1,270 samples, 321 subjects with two measures remained in the analysis (Figure2.1a,c).
The average time difference between the two LP dates was 6.14 years, and the standard deviation
was 2.98 years. The overall Pearson’s correlation coefficient between two LP dates was 0.995,
with a 95% confidence interval from 0.99518 to 0.99526 (Figure2.1c).
The overall high correlations within each tissue indicated that the aptamer-based technology was
highly reproducible.
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2.2.4 Genomic data QC process
Most of the samples with proteomic profiling were collected with genotyping data (Fig1.3d). For
CSF, 965 out of 971 unique subjects have both genotype and proteomic data. For plasma, 633
out of 636 unique subjects have both genotype and proteomic data. For brain tissue, 450 out of
458 unique subjects have both genotype and proteomic data.
Samples were genotyped on multiple genotyping platforms from Illumina. Stringent quality
thresholds were applied to the genotype data for each platform separately. SNPs were kept if
they passed all the following criteria: i) genotyping successful rate >= 98% per SNP or per
individual; ii) MAF >= 0.01; iii) Hardy-Weinberg equilibrium (HWE) (p >=1× 10-6).
After removing low quality SNPs and individuals, genotype imputation was performed using the
Impute2 program55 with haplotypes derived from the 1,000 Genomes Project (released June
2012). Genotype imputation was performed separately based on the genotype platform used.
SNPs with an info-score quality of less than 0.3 reported by Impute2, with a MAF < 0.02, or out
of HWE were removed. After imputation and QC, the different imputed PLINK files were
merged. A total of 14,059,245 imputed and directly-genotyped SNPs and 1,530 individuals were
used for final analyses. To adjust for population substructure (Figure2.3d), principal component
analysis (PCA) was conducted using the PLINK1.9 (v1.90b6.4)56 subcommand “pca”. HapMap
samples (CEU: Caucasian Europeans from Utah; JPT: Japanese in Tokyo; YRI: Yoruba in
Ibadan, Nigeria) were included in the analyses to remove outliers and confirm self-reported
ethnicity. Samples within the CEU cluster were kept. To identify unanticipated duplicates and
cryptic relatedness using pair-wise genome-wide estimates of proportion identity by descent
(IBD) (Figure2.3d), the subcommand IBD from PLINK1.9 (v1.90b6.4)56 was used. When
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duplicate samples or a pair of samples with cryptic relatedness (PI_HAT >= 0.5) were identified,
one sample from the pair was removed. A total of 835 CSF, 529 plasma, and 380 brain samples
passed filters on both genomic and proteomic QC.

2.2.5 pQTL identification
To test for the association between genetic variants and protein levels, I performed a linear
regression (additive model), including age, sex, principal component factors from population
stratification, and genotype platform as covariates:

cis-pQTL mapping. I conducted cis-pQTL mapping within each of the three tissues. Only
proteins passing QC were included in the analyses. Protein level was 10-based logarithm
transformed to approximate the normal distribution. Within each tissue, cis-pQTL were
identified by linear regression, as implemented in PLINK2 (v2.00a2LM)56, adjusting for sex,
age, the first two genotype-based principal components (PCs) [genetically very homogeneous],
and genotyping platforms (Omni1, Omini2.5, NeuroX). I restricted our search to variants within
1 Mb upstream and downstream of the gene start site by which each protein is coded. Actual pvalues for each variant–protein pair were estimated using an additive linear regression model. To
identify the list of all significant variant–protein pairs, variants with an actual p-value below the
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genome-wide significance (5×10-8) level were considered significant and included in the final
list.

trans-pQTL mapping. PLINK2 (v2.00a2LM)56 was used to test all autosomal variants (MAF
Freq>0.02) using the same QC pipelines as cis-pQTL mapping, but was restricted to variants and
proteins encoded by the genes locating outside the 2Mb window in each tissue independently
using an additive linear model. For trans-pQTL mapping, I tested variants for association with
the same protein list as for cis-pQTL mapping. I included the covariates of the first two genotype
PCs [genetically very homogeneous], age, sex, and genotyping platforms when performing
association tests. The correlation between variant and protein levels was evaluated using an
additive linear regression model. To identify the list of all significant variant–protein pairs,
variants with an actual p-value below the study-wide significance (5×10-8/number_PCs) were
considered significant and included in the final list. The number of PCs was derived as the
minimum principal component number that cumulatively explain 95% of the variance for each
tissue after QC. For CSF, plasma, and brain, the number of PCs is 169, 230, and 75, respectively.
Thus, the p-value thresholds are 2.96×10-10, 2.17×10-10, and 6.67×10-10, respectively.

Disease specific analyses: To investigate a disease-specific effect on pQTLs, I performed linear
regression on the same protein-loci pairs (before conditioning on top variants) identified from the
above default model using three additional models: 1) joint analysis including disease status as
another covariate (CO vs non-CO); 2) AD case (CA) only using the same covariates as the
default model; 3) cognitive unimpaired (CO) only using the same covariates as the default
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model. Using scatterplots, I visualized the correlation between each of the additional models and
our default model. Using model 1 for comparison, we observed a Pearson correlation coefficient
of 0.999, 0.999, 0.999 for CSF, plasma, and brain, respectively. Using model 2 for comparison, I
observed a Pearson correlation coefficient of 0.991, 0.989, 0.998 for CSF, plasma, and brain,
respectively. Using model 3 for comparison, I observed a Pearson correlation coefficient of
0.999, 0.998, 0.602 (p-value = 0.002) for CSF, plasma, and brain, respectively. The relatively
low correlation seen when using model 3 for comparison with controls only in brain samples was
due to a much smaller sample size (n=24).

Age-specific analyses: To confirm that none the of findings were age specific, I performed
separate analyses in participants younger and older than the average age of our cohort and
compared the β1 of SNP dosage for all significant pQTLs to identify any age-specific effect.

Variance explained by the top variant on certain protein: I calculated the adjusted R-squared
value using the linear regression model with the top variant as the only predictor and the log10based certain protein abundance as the outcome. To account for variance explained by
covariates, I also calculated the adjusted R-squared value using a nested model and the estimates
were like using the top variant as the only predictor (Figure2.4).
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Figure2.4 Scatterplots on the correlation of the adjusted R-square estimates from two models (X-axis: linear
regression model with the top variant as the only predictor; Y-axis: nested model with top variant after controlling
for covariates)

2.2.6 Replication strategy for CSF pQTLs
To replicate our pQTL findings with all previously reported pQTLs from large-scale proteinlevel GWAS (pGWAS), I performed CSF replication analyses. I first searched the reprocessed
pQTL results using Sasayama et al., 2017 (SOMAscan-based, CSF); Parkinson's Progression
Markers Initiative112 (released December 2019, PPMI19 hereafter; SOMAscan-based, CSF); and
meta-analysis of these two prior studies. Next, I checked summary statistics from INTERVAL
(SOMAscan-based, plasma). Finally, I queried other plasma pGWAS findings from EBI-NHGRI
using phenoscannerV2 57 with proxy SNPs (r2 > 0.5) (Figure2.7b).
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Reprocessing pQTLs using Sasayama 2017 CSF SOMAscan individual data: I decided to
reprocess the genetic data because the original study used unimputed genotype data. I also
reprocessed all the proteomic data using similar pipelines to the one for the replication data. I
performed imputation in the Sasayama data to have a similar number of SNPs across studies. For
proteomics QC, only the IQR strategy was used, as neither calibrator nor positive/negative
control values were provided. (QC Positive is a technical sample provided with the SOMAscan
platform for use as a positive control. Similarly, QC Negative is a technical sample used as a
negative control). Protein outliers were identified if the subject was located outside of either end
of distribution using 1.5-fold of IQR given the log10 transformation of the protein level.
Collectively, if the number of outliers given an analyte was greater than 85% of total sample
size, this analyte was filtered. Next, an orthogonal approach was used to call subject outliers
based on IQR. Collectively, if the number of outliers given an analyte was greater than 85% of
total number of analytes passed QC, this subject was labeled as an outlier. Overall, 1,128
proteins and 133 subjects passed protein data QC. Genotype data QC and imputation was
performed as described above. A total of over 5 million (5,187,563) imputed and directlygenotyped SNPs and 154 individuals were used for final analyses. Population substructure
analyses was performed as described above, except samples kept were within the JPT cluster. A
total of 132 CSF samples from study by Sasayama and colleagues passed filters on both
genomics and proteomics QC. I performed linear regression (additive model), including first two
principal component factors from population stratification as covariates.

Reprocessing pQTLs using PPMI19 CSF SOMAscan data: To replicate CSF pQTL, I performed
linear regression on all 709 shared proteins between the WU and PPMI19 CSF proteomic data
30

using the proteomic and genotype data from PPMI19. I performed protein QC, genotype
imputation and QC, and analyses using the same protocols as those used for the data generated in
this study and described above. A total of over 7 million (7,392,620) whole-genome sequenced
SNPs and 132 CSF samples from study by PPMI19 passed filters on both genomics and
proteomics QC. I performed a linear regression (additive model), including age, sex, and first
two principal component factors from population stratification as covariates.

Meta-analyses on pQTLs using summary statistics from single studies I performed fixed effect
meta-analyses using METAL58 based on inverse-variance weighting. Overall, I performed four
different combinations of meta-analyses: 1) meta1_PPMI19_JP17: meta-analysis on both the
CSF studies by Sasayama et al. 2017 and by PPMI19; 2) meta2_WUcsf_PPMI19_JP17: metaanalysis on all three CSF studies by Sasayama et al. 2017, by PPMI19, and by Washington
University cohort (this study); 3) meta3_WUcsf_WUplasma_WUbrain: meta-analysis on all
three-tissue findings from CSF, plasma, and brain by Washington University cohort (this study);
4) meta4_ WUcsf_WUplasma_WUbrain_ PPMI19_JP17: meta-analysis on both the CSF studies
by Sasayama et al. 2017 and by PPMI19 plus all three-tissue findings from CSF, plasma, and
brain by Washington University cohort (this study).

2.2.7 Replication strategy for plasma pQTLs
To identify all previously reported pQTLs from large-scale protein-level GWAS, I performed
plasma replication analyses using the following strategies. I first searched the reprocessed pQTL
results using AddNeuroMed (SOMAscan-based, plasma). Next, I checked summary statistics
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from INTERVAL (SOMAscan-based, plasma). Finally, I queried other plasma pGWAS findings
from EBI-NHGRI using phenoscannerV2 with proxy SNPs (r2 > 0.5).

Reprocessing pQTL using AddNeuroMed plasma SOMAscan data: To replicate plasma pQTLs,
I performed linear regression on all proteins using the proteomic and genotype data from the
AddNeuroMed consortium59. A total of over 7 million (7,313,640) imputed and directlygenotyped SNPs and 343 plasma samples from the study by AddNeuroMed passed filters on
both genomics and proteomics QC. I performed a linear regression (additive model), including
age, gender, first two principal component factors from population stratification, centers, status,
visit cohorts, and batch effects as covariates.

2.2.8 Replication strategy for brain pQTLs
To identify all previously reported pQTL from large-scale protein-level GWAS, I performed the
brain replication analyses using the following strategies. I first searched the processed pQTL
results using results from the published brain findings47. Next, I queried all plasma pGWAS
findings from EBI-NHGRI using phenoscannerV2 and from our CSF findings.
For each locus, I investigated whether the sentinel SNP or a proxy (r2 > 0.5) was associated with
the same target protein (or aptamer) in our study at different defined significance thresholds. For
the known category in our primary assessment, I used a p-value threshold of 5×10-8. For the
replicated category in our primary assessment, I used a p-value threshold of 5×10-2.
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2.2.9 Annotation of pQTLs
All significant pQTLs (hg19) were annotated using ANNOVAR60 version (2018-04-16) with the
option -geneanno in gene-based annotation mode. Genomic features and variants affecting the
nearest genes were used for downstream analyses. The bar plots were drawn using the ggplot261
R package.

2.2.10 Testing for genomic feature enrichment
I used Fisher’s exact test (two-sided) for testing the enrichment. The null set was set using pvalue > 5×10-8 and permutated with the same amount of variants as the positive-set. The various
groupings were determined by ANNOVAR version (2018-04-16). I also tested whether our
pQTL were enriched for functional and regulatory characteristics using GARFIELD
v262.GARFIELD is short for GWAS Analysis of Regulatory or Functional Information
Enrichment with LD correction, and it is a method to test feature enrichment by integrating
GWAS findings and a large set of regulatory or functional annotations (1005 features in total)
mainly from ENCODE and Roadmap epigenomics consortia. It considers the LD while
annotating and calculating enrichments. The enrichment is quantified as odds ratio (OR).
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2.3 Results
2.3.1 Discovery of multi-tissue pQTLs
We generated data for 1,305 proteins using an aptamer-based platform31 in CSF (n=971), plasma
(n=636), and brain (n=459) samples (Figure2.2). We included multiple technical and biological
replicates to confirm the replicability and reproducibility of our proteomic measurements
(Figure2.3). I performed stringent quality control (QC) steps for the proteomic data (See
Methods). After QC, 835 CSF samples and 713 proteins, 529 plasma samples and 931 proteins,
and 380 brain samples and 1079 proteins were included in the analyses. The cohort included
individuals with AD and cognitively normal individuals of European ancestry (Table2.2).
Table2.2 Demographics of the baseline cohort after QC
CSF
Plasma
Brain
N
835
529
380
Age [mean+/-sd]
69.4+/-9.3
69.8+/-9.4
83.3+/-10
Female (%)
53%
54%
57%
% CDR=0
74.37%
68.24%
11.57%
APOE e4 (%)
38%
41%
48%
Characteristics of the baseline cohort after QC, including age, gender, Alzheimer disease status (as Clinical
Dementia Rating (CDR)) and APOE e4 allele percentage. For CSF, age denotes age at lumbar puncture; For
plasma, age denotes age at plasma draw; For brain, age denotes age at death. Values are reported in years (mean ±
standard deviation [sd]).

To identify pQTLs within each tissue (Figure2.5a), I performed genome-wide association
analyses of 4.09 million imputed autosomal common variants (minor allele frequency (MAF)
0.02) against protein levels in each tissue. I defined cis-signals as those where the single
nucleotide polymorphism (SNP) fell within 1Mb upstream or downstream of the gene start site,
which may not include all enhancers for the corresponding gene. Trans-signals are defined as
those where the SNP fell outside of the 2Mb window. To correct for multiple tests, I used a
stringent genome-wide threshold of p<5×10-8 for cis-pQTLs and 5×10-8/(number-of34

independent-proteins) for trans-pQTLs. There were 169, 230, and 75 independent proteins in
CSF, plasma, and brain, respectively (see Methods). Therefore, p-value thresholds were set at
2.96×10-10 for CSF, 2.17×10-10 for plasma, and 6.67×10-10 for brain.
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Figure2.5 Study design and overview of the significant pQTLs within each tissue. (a) Schematic of study
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design. CSF, plasma, and brain tissues were profiled using a high-throughput aptamer-based proteomics platform.
We identified common genetic variation within each tissue associated with each protein after integrating both the
genotype for each variant and protein level. (b) Table of sample size after QC and total number of pQTLs (split by
cis, P < 5×10-8, and trans P < 5×10-8/number_PCs) for each tissue. For trans-pQTLs, the p-value cutoff for CSF is
3×10-10 (5×10-8/169), for plasma it is 2×10-10 (5×10-8/230), and for brain it is 7×10-10 (5×10-8/75). Trans* represents
replication of trans-pQTLs given genome-wide significance (p-value < 5×10-8). (c) Stacked Manhattan plots for all
three tissues mapping genomic locations of these pQTL within each tissue (cis: dark-green; trans: gold). The X- axis
denotes the positions of the common variants.

In total, I identified 274 significant independent (defined in details in Chapter3) pQTLs for 184
CSF proteins, 127 independent pQTLs for 100 plasma proteins, and 32 independent pQTLs for
27 brain proteins (Figure2.5b,c,d). The number of significant pQTLs was proportional to the
sample size, rather than the number of proteins. Of the 274 significant associations in CSF
(25.8% of total proteins, 184 vs 713), 82% were cis associations and 18% were trans
associations. In plasma (10.7% of total proteins, 100 vs 931), 76% were cis associations and 24%
were trans associations. Lastly, in brain (2.5% of total proteins, 27 vs 1079), 94% were cis
associations and 6% were trans associations (Figure2.5b,c). I next investigated the distance
between trans-pQTLs from the transcription start site of their respective genes to discover how
many trans-pQTLs are inter-chromosomal or intra-chromosomal. I found that 91.5 to 98.9% of
the trans-pQTLs were inter-chromosomal.

2.3.2 Replication and meta-analyses using independent datasets
To replicate our pQTL findings, I analyzed several publicly available datasets as explained on
Materials and methods sections 2.2.6, 2.2.7, and 2.2.8 (Figure2.6a-c, Figure2.7a,b). I also
performed meta-analyses and cross-tissue replication.
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Figure2.6 Overview of the replication of the pQTLs within each tissue. (a-c) Tables of replication of these
pQTLs within CSF, plasma, and brain, given different p-value thresholds for different datasets. Overall, we
classified pQTLs into five mutually exclusive groups: 1) known pQTLs in the matched-tissue (single-study) with a
p-value less than 5×10-8; 2) replicated pQTLs in the matched-tissue with a p-value less than 5×10-2 but greater than
or equal to 5×10-8 [NOTE: for CSF, we split this group into two sub-groups: 2a) replicated only in the meta-analysis
of two external CSF studies with a p-value less than 5×10-8; 2b) replicated pQTLs in the matched-tissue with a pvalue less than 5×10-2 but greater than or equal to 5×10-8]; 3) replicated pQTLs in the other tissues with a p-value
less than 5×10-2; 4) pQTLs found in any tissues (matched or not) with a p-value greater than or equal to 5×10-2; 5)
unknown (either protein or SNP missing). For CSF, we further split the 2nd group into 2a) replicated pQTLs in the
matched-tissue (meta-analysis) with a p-value less than 5×10-8 and 2b) replicated pQTLs in the matched-tissue
(meta-analysis and/or single-study) with a p-value less than 5×10-2 but greater than or equal to 5×10-8. Trans*
represents replication of trans-pQTLs given genome-wide significance (p-value < 5×10-8) but not necessarily
passing study-wide significance.

For CSF (Figure2.6a), I found 274 independent pQTLs, of which 223 (81.3%) were novel. I
leveraged two CSF studies in which similar proteomic and genetic data were available.
Sasayama et al. generated aptamer-based proteomic and array-based genotype data from 132
samples of Japanese origin29 and the PPMI (n=131) also had proteomics and genotype data
available. I found that 51 pQTLs (49 cis and 2 trans, 18.6%) identified in our study have
genome-wide significance with effects in the same direction in at least one the replication
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studies. I also performed a meta-analysis of the Sasayama and PPMI19 studies to identify
additional genome-wide and nominal associations. I found that 153 (55.8%) of our significant
signals had genome-wide significance in our meta-analysis of the PPMI19 and Sasayama studies
and 27 (9.9%) additional pQTLs showed at least a nominal association (p-value < 0.05) in the
same direction. I also identified an additional 16 (5.8%) pQTLs that have been reported as
pQTLs in other tissues (plasma studies from AddNeuroMed63, INTERVAL25, KORA24,
SCALLOP23, the Phenoscanner database57, a brain mass spectrometry-based pQTL study47, and
in our plasma or brain pQTL data). I was unable to test for replication of 5 (1.8%) pQTLs as
protein levels were not available in these other studies. In summary, I was able to replicate more
than 90.1% of the CSF pQTLs, which is higher than in previous studies25. Twenty-two (8.1%)
pQTLs are still pending replication, as current CSF studies with smaller sample sizes do not
provide enough statistical power. However, based on our validation with plasma and brain
pQTLs, I estimate that more than 90% of those pQTLs are real. This is supported by the fact that
I have been able to replicate 96.8% and 96.9% of plasma and brain pQTLs (see below).
For plasma (Figure2.6b), I found 127 independent pQTLs, of which 17 were novel. For
replication of plasma pQTLs, we used the five studies mentioned above. I was able to replicate
96.8% of our 127 pQTLs. I was unable to test 2 (1.6%), as they were not measured in those
studies. For brain (Figure2.6c), I found 32 independent pQTLs, of which 27 were novel. As
there were no published studies using the same aptamer-based proteomic method, I matched our
proteins with a mass spectrometry-based pQTL dataset47. I was able to replicate 5 (15.6%)
signals at genome-wide significance, 8 (25%) signals at a nominal (p-value < 0.05) association,
and 18 (56.3%) pQTLs that showed at least a nominal association in brain or CSF. Only 1 (3.1%)
pQTL was not replicated.
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2.3.3 Meta-analyses of pQTLs
To increase statistical power and to identify additional genome-wide significant pQTLs, I
performed meta-analyses that included all CSF cohorts as well as multi-tissue analyses. I first
performed a CSF meta-analysis including the 596 common proteins shared among our study,
PPMI19, and the Sasayama study (Figure2.7c,d). Due to the increased sample-size, I identified
425 pQTLs for 310 proteins, compared to 250 pQTLs for 185 proteins identified in our CSF
cohort alone. This represents a nearly twofold increase in pQTL signals by increasing the sample
size by 25%, suggesting that more pQTLs will be identified with larger sample sizes. I observed
a similar increase in the number of pQTLs when performing a multi-tissue meta-analysis. For
these analyses, I included 342 proteins that passed QC in all three tissue types as well as the
PPMI19 and Sasayama study. I found 253 pQTLs compared to the 139 that were found in our
CSF cohort alone (Figure2.7c,d).
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Figure2.7 Overview of the sample size and number of pQTLs from pQTL studies mentioned in this paper and
the summary statistics from the meta-analyses. (a) Scatter plot of sample size (log10-scaled) and number of total
pQTLs after clumping or unique proteins when no clumping was performed (log10-scaled). Dot color represents the
tissue type; dot size represents total number of proteins profiled. (b) Table of these nine datasets listed the exact
numbers for drawing the scatter plot. (c) Table of three different combinations of meta-analyses: 2)
meta2_WUcsf_PPMI19_JP17: meta-analysis on all three CSF studies by Sasayama and colleagues published in
2017, by PPMI released in 2019, and by Washington University cohort (this study); 3)
meta3_WUcsf_WUplasma_WUbrain: meta-analysis on all three-tissue findings from CSF, plasma and brain
respectively by Washington University cohort (this study); 4) meta4_ WUcsf_WUplasma_WUbrain_
PPMI19_JP17: meta-analysis on both the CSF studies by Sasayama and colleagues published in 2017 and by PPMI
released in 2019 plus all three-tissue findings from CSF, plasma and brain respectively by Washington University
cohort (this study). The columns include number of proteins in common, number of protein-level GWAS hits after
meta-analysis, number of protein-level GWAS hits before meta-analysis using only the common proteins within
each tissue for each combination. (d) Stacked Manhattan plots for all three different combinations of meta-analyses.
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2.3.4 Determination of disease-specific and age-specific pQTLs
Because our study includes cognitively normal older individuals and AD cases, I performed
additional analyses to determine if any of the pQTLs are disease- or age-specific. To investigate
a disease-specific effect, I first included disease status as a covariate. Next, I performed caseonly and control-only analyses. Finally, I compared the effect sizes of the genome-wide
significant pQTLs from the initial analyses with the beta of these analyses. I found an extremely
high correlation (Pearson’s r>0.98, Figure2.8) indicating that the association of the genetic
variants with protein levels are not disease-specific. To investigate an age-specific effect, I
performed separate analyses in participants younger than or older than the average age of our
cohort and compared the effect sizes of the genome-wide significant pQTLs from the initial
analyses with the beta of these analyses. I found an extremely high correlation (Pearson’s
r>0.98), indicating that few pQTLs are age-specific.
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Figure2.8 Disease stratified analysis on comparing pQTLs effect size. To investigate of disease status effect on
pQTLs, we performed linear regression on the same protein-loci pairs (before conditioning on top variants)
identified from above default model using three additional models: (a) joint analysis but with disease status as
another covariate (CO vs non-CO). Pearson correlation coefficient was 0.999 (p-value < 2.2×10-16, 95%CI = 0.999
to 0.999), 0.999 (p-value = 4.3×10-202, 95%CI =0.999 to 0.999), 0.999 (p-value = 9.5×10-52, 95%CI = 0.999 to
0.999) for CSF, plasma, and brain respectively. Sample size for this joint analysis was 835, 529, and 380 for CSF,
plasma, and brain respectively. (b) AD case (CA) only using the same covariates as default model. Pearson
correlation coefficient of 0.991 (p-value = 3.9×10-160, 95%CI =0.988 to 0.993), 0.989 (p-value = 1.8×10-83, 95%CI
=0.983 to 0.992), 0.998 (p-value = 2.4×10-29, 95%CI =0.995 to 0.999) for CSF, plasma, and brain respectively.
Sample size for this AD case (CA) only analysis was 217, 168, and 248 for CSF, plasma, and brain respectively. (c)
Cognitive unimpaired (CO) only using the same covariates as default model. Pearson correlation coefficient of
0.999 (p-value = 5.2×10-234, 95%CI =0.998 to 0.999), 0.998 (p-value = 1.17×10-122, 95%CI =0.997 to 0.999), 0.602
(p-value = 0.002, 95%CI =0.262 to 0.809) for CSF, plasma, and brain respectively. Sample size for this cognitive
unimpaired (CO) only analysis was 614, 357, and 24 for CSF, plasma, and brain respectively. The relatively low
correlation in default model comparison with control only in brain samples was due to much smaller sample size as
a control for brain samples.

2.3.5 Functional annotation and biological mechanisms underlying pQTLs
Previous studies discovered that most eQTLs are non-coding variants leading to the hypothesis
that most eQTLs modulate transcription factor binding or chromatin structure20. However, it
remains elusive if this is the case for pQTLs. For this reason, I performed bioinformatic
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functional annotation and statistical analyses to determine if pQTLs are enriched in specific
regions, such as untranslated regions (UTRs), downstream or upstream of genes, introns, exons,
splice sites, non-coding RNA (ncRNA) splice sites, ncRNA_introns, ncRNA_exons, or
intergenic regions. I found that the strength of the association (negative log10 p-value) for cissignals decreased with distance from the transcription start site (Figure2.9a), similar to what has
been previously reported for cis-eQTLs20. This effect was found in all three tissues, suggesting
that this is a common biological event. There was an inverse relationship between absolute value
of the effect size (beta) and MAF (Figure2.9b), which is consistent with previous protein-level
genome-wide association studies25,64.However, both cis- and trans-pQTLs were strongly
enriched for synonymous and non-synonymous exonic variants (Odds Ratio = 3.71, 5.25, 4.19
for CSF, plasma, and brain, respectively; Figure2.9c). For 42 to 53% of cis-pQTLs (95 out of
226 in CSF, 44 out of 97 in plasma, and 16 out of 30 in brain), the association can be explained
by a coding-variant, whereas for cis-eQTLs65 only 2 to 5% of signals are located in coding
regions. This indicates that pQTLs are significantly enriched for coding-variants. These results
suggest a role for additional regulatory mechanisms (including post-transcriptional changes), as
protein levels may not correlate with mRNA levels.
The enrichment of coding-variants for pQTLs in cis and trans (Figure2.9c) suggests that protein
levels are likely to be regulated post-transcriptionally rather than by regulating mRNA level66.
Cis-pQTLs could lead to changes in protein levels by affecting the signal or the cleavage peptide.
For trans-pQTLs, these variants could alter function of a receptor of the protein, affect the
machinery that cleaves proteins from the membrane, or regulate the function a gene encoding a
transcription factor. This coding-variant enrichment observations may be confounded by
aptamer-binding effects inherent to the aptamer-based platform. In multiple cases, the most
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significant signal was a coding-variant in a gene that affects protein cleavage or secretion (cissignal; as in the case of IL6R or YKL-40; Figure2.9c), or a coding-variant in the receptor of the
protein that is likely to modify protein-receptor binding (trans-signal; as in the case of variants in
the APOC4 gene region associated with the BAFF Receptor; Figure2.9c). In line with the
hypothesis that coding-variants have a greater effect size and that pQTLs are enriched for
coding-variants, I found that pQTLs explained a large proportion of the variation in protein
levels. The median variation in protein levels explained by pQTLs (adjusted R-squared
calculated using the top variant as the only predictor and again using a nested model accounting
for the covariates) was 9 to 14.9% (interquartile range: 13.2 to 15%; Figure2.9d). However,
there were some extreme cases in which the top pQTL explained more than half of the variability
in protein levels. For example, rs2075803 (p.K100E) explained 81% of CSF Siglec-9, rs5498
(p.K469E) explained 74.4% of plasma sICAM-1, and rs5498 (p.K469E) explained 67.4% of
brain PPAC (Figure2.9d). CSF Siglec-9, plasma sICAM-1, and brain PPAC have been
replicated in other studies47,64,67,68 using a different proteomic approach, which indicates that
these findings may not be driven by platform.
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Figure2.9 Properties and bioinformatic annotation of pQTLs. (a) Dot plots of -log10(P) from all significant
associations (via linear regression) against the distance of sentinel SNPs from TSS within each tissue. (b) Dot plots
of absolute effect size associated with MAF within each tissue. (c) Forest plot of enrichment on the predicted
functional annotation classes of pQTLs versus null sets of variants from permutation within each tissue and Bar
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plots of the proportion of variants annotate in each class. (Note: Features on
exonic_splicing/ncRNA_splicing/splicing/UTR5_UTR3 are not shown due to not all tissues have these features). (d)
Histograms of variance explained by conditionally independent variants within each tissue. For CSF, the mean =
0.141, standard deviation = 0.144, mode = 0.061; For plasma, the mean = 0.157, standard deviation = 0.125, mode =
0.188; For brain, the mean = 0.208, standard deviation = 0.151, mode = 0.092.

2.4 Conclusions
In this aim, I identified and replicated pQTLs within each tissue, specifically for CSF and brain.
To my knowledge, the first multi-tissue and largest cohort for high-throughput proteomic studies
integrating with the genotype data as of April 2021.
This study has two limitations. The first limitation is that we used an aptamer-binding platform
to profile proteomics, which might be confounded by recognition difference instead of real
protein abundance change, as already addressed by Sun et al25. Mass spectrometry can be a
complementary platform66 that will not be affected by this problem. Our observation of an
enrichment of coding-variants in pQTLs could be largely biased by the platform. However, I
found 83 to 90% of our non-coding pQTL and 10 to 17% coding pQTL, respectively and
depending on tissues, were also seen in a mass spectrometry-based pQTL study47. The
percentages for coding variants were similar (Proportional-test: p-value > 0.05 in all three
tissues), indicating that this enrichment was not exclusively due to the bias of a single
technology. For the second limitation, our data suggest that pQTLs are in coding regions more
often than are eQTLs, and our results could be biased, because coding pQTLs have stronger
effects than non-coding pQTLs. Therefore, non-coding pQTLs may remain undetected due to a
lack of statistical power. However, the sample size of our study is similar to or larger than GTEx
for brain-relevant tissues, and eQTL studies from GTEx do not see the same amount of codingvariant enrichment65.
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Additional studies performed in more tissues and using approaches that include an even larger
number of proteins are necessary to better understand the genetic architecture of protein levels
and to replicate these findings.
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Chapter 3: Identification of independent
local pQTLs and pleiotropy regions
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3.1 Introduction
It has been reported that one locus can harbor multiple independent genome-wide significant
variants. Deming and colleagues40 reported two independent genome-wide significant variants
within MS4A locus associated with CSF soluble-TREM2 protein level. Stepwise regressionbased conditional analysis can be used to identify independent variants. It would be useful to
identify independent genome-wide significant variants with a much larger proteomics dataset.
Pleiotropy is defined as one genetic variant associated with more than one molecular phenotype.
Deming and colleagues32 reported that three pleiotropic regions using a plasma proteomics
dataset: ABO, FTU2, APOE. The pleiotropic regions can be termed as master regulators; thus, it
would be interesting to identify these regulators in a larger proteomics dataset and not only
within plasma, but also in other tissues.

3.2 Materials and methods
3.2.1 Conditional analysis on independent local pQTLs
To identify independent significant local pQTLs, I performed a conditional analysis on all
pQTLs from the initial analyses (round_0) using PLINK2 (v2.00a2LM)56 with the --condition or
--condition-list option. I used the same significance threshold of p-value = 5×10-8 used for the
univariable analysis on identifying independent local pQTLs within a window size of 2Mb.
Conditional analyses were performed as follows: Before conditional (row-1; round_0), no SNPs
were used as a covariate given one region. For the first round of conditional analyses (round_1;
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row-2), the top SNP from the before-conditioning stage given the same region was used as an
additional covariate in the default model. For the second round (round_2; row-3), the top SNPs
from both the before-conditioning stage and round_1 stage were used as an additional covariate
in the default model. Both SNPs were within the same region. This iteration was continued for
each round by adding one more top SNP from the prior round until no variants passed the
genome-wide significance threshold given the same region. For CSF and plasma samples, in
total 4 rounds of conditional analyses were performed. For brain samples, 3 rounds of
conditional analyses were performed. The results were visualized using locusZoom v1.369.

3.2.2 Identification of pleiotropic regions
To identify unique non-overlapping regions associated with a given an aptamer, I first defined a
2Mb region 1Mb upstream and 1Mb downstream of each significant variant for that aptamer.
Within the 2Mb region containing the variant with the smallest p-value any overlapping regions
were then merged into the same locus. To identify whether a region was associated with multiple
protein levels, measured by the aptamer-based technology, I next used an linkage disequilibrium
(LD)-based clumping approach (LD block from the 1000 Genome Project implemented into the
ROGHE70 R package, as I also used 1000 Genome Project as our imputation reference panel).
Variants were combined into a single region per LD (EUR) defined loci. Any loci associated
with more than one protein were identified as pleiotropic regions. The cytoband ID was also
annotated. Circos plots were generated using functions from R package circlize71.
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3.3 Results
3.3.1 Disentangling independent local pQTLs
To identify independent local pQTLs where more than one association exists within 1Mb up- or
downstream of the region’s top variant, I performed conditional analyses. After the first round of
conditional analyses, 55 CSF, 22 plasma, and 5 brain loci still had SNPs with independent and
genome-wide significance (Figure3.1a). I performed a second round of conditional analyses
including the top SNPs from the initial and first conditional analyses. In the second round, 23
CSF, 6 plasma, and 1 brain loci still showed independent and genome-wide significant
associations (Figure3.1a). I continued performing conditional analyses until no SNPs passed the
genome-wide threshold. I found 1 protein with up to 5 independent signals, 10 proteins with 4
independent signals, and 30 proteins with 3 independent signals. This highlights the complexity
of regions with multiple independent local pQTLs that regulate protein levels.
As an example of these complex regions, the main signal for CSF ARTS1 (Figure3.1b) was
primarily associated with the nonsynonymous variant p.R725Q (rs17482078, p-value = 8.64×1095

). After conditioning on this signal, there was still a genome-wide signal tagged by rs467735

(conditional p-value=9.82×10-89) that was associated with gene expression (GTEx; multi-tissue
p-value=0 [NOTE: online result https://gtexportal.org/home/snp/rs467735, Meta Analysis new
random effect (RE2) result on this cis-eQTL]). I found two additional independent signals for
this region. Similarly, there are four independent variants for CSF ASAHL (Figure3.1c).
Together, these results indicate that proteins are highly regulated and include several
independent mechanisms, even in the same region. These mechanisms may affect not only gene
expression (eQTL), but also protein level by affecting cleavage, cell secretion, receptor binding,
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or clearance in the case of nonsynonymous variants. One example of such regulation by
nonsynonymous variants is IL6R, which had a strong cis-pQTL that was primarily associated
with the coding-variant rs2228145 p.D358A (and rs12730935 which was in perfect LD;
plasma=1.6×10-105 CSF= 1.3×10-104), as this variant leads to increased cleavage by ADAM10
and ADAM17 of the membrane bound IL-6R72.
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Figure3.1 Identification of conditionally independent local pQTLs. (a) Tables of conditionally independent
pQTLs (cis and trans) locally (2 Mb window) after each round for each tissue. Before conditional, no SNPs were
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used as a covariate given one region. For round_1 conditioning, the top SNP from before-conditioning stage given
the same region was used as an additional covariate in the default model. For round_2 conditioning, the top SNP
from before-conditioning stage and top SNP from round_1 stage was used as an additional covariate in the default
model. Both SNPs were within the same region. For each round we added the previous independent top hits from the
prior rounds until no variants passed genome-wide significance threshold given the same region. (b) Regional
association plots of the ERAP1 region associated with CSF ARTS1 protein: (round_0) before conditional analyses,
centered on rs17482078; (round_1) after conditioning on the prior top SNP (rs17482078, centered on rs467735;
(round_2) after conditioning on the prior top SNPs (rs17482078 and rs467735, centered on rs141244362; (round_3)
after conditioning on the prior top SNPs (rs17482078 and rs467735 and rs141244362, centered on rs153541. No
genome-wide significant SNPs was observed in round_4 after conditioning on all prior top SNPs. (c) Regional
association plots of the NAAA region associated with CSF ASAHL protein: (round_0) before conditional analyses,
centered on rs66498356; (round_1) after conditioning on the prior top SNP (rs66498356, centered on rs112222416;
(round_2) after conditioning on the prior top SNPs (rs66498356 and rs112222416, centered on rs6823734;
(round_3) after conditioning on the prior top SNPs (rs66498356 and rs112222416and rs6823734, centered on
rs13126007. No genome-wide significant SNP was observed in round_4 after conditioning on all prior top SNPs.
The SNPs for each regional plot are denoted as a purple diamond. Each dot represents individual SNPs, and dot
colors in the regional plots represent linkage disequilibrium with the named SNP at the center. Blue vertical lines in
the regional plots show recombination rate as marked on the right-hand Y-axis.

3.3.2 Pleiotropic loci
Besides identifying multiple local pQTLs, I found that some loci were associated with the levels
of more than one protein, and up to 13 different proteins in the case of genetic variants in the
APOE region. Prior findings reported that the APOE locus is a pleiotropic region using plasma
proteomics datasets, and I found this in CSF as well. Genetic variants in the APOE gene region
were associated with 13 different CSF proteins, including Apolipoprotein E (isoform E2) (APOE
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E2) and 14-3-3 (Figure3.2, Figure3.3a, Figure3.4a). The genes encoding these proteins were
located on different chromosomes indicating that this is not just cis regulation. Variants in the
APOE locus are the strongest genetics risk factors for AD. Several studies have found that the
14-3-3 protein is a marker of non-specific neuronal death73,74, and our results indicated that 14-33 protein was also regulated by the APOE locus. For CSF, I found 59 pleiotropic regions where a
single locus was associated with 2 or more proteins. In plasma, I replicated the known pleiotropy
of the ABO locus for 7 different proteins, including E-Selectin (Figure3.3b, Figure3.4b), which
was implicated in stroke risk by a recent study75. Further studies are needed to establish how
these genetic variants are associated with multiple proteins. For example, genetic variants in the
SPCS3-VEGFC region regulated levels of 5 different brain proteins including Angiopoietin-1
and Growth hormone receptor (Figure3.3c, Figure3.4c). I found an additional pleiotropic
regions in plasma and in brain proteins respectively.

Figure3.2 Summary of all pleiotropic regions within each tissue. These results used genome-wide significance
threshold for both cis and trans-pQTLs and the name of top-1 locus ranked by number of unique proteins.
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Figure3.3 Top-1 pleiotropic region within each tissue. (a) Circos plot of top-1 locus (mapped to APOETOMM40) associated with 13 unique CSF proteins. (b) Circos plot of top-1 locus (mapped to ABO or HRG)
associated with 7 unique plasma proteins. (c) Circos plot of top-1 locus (mapped to SPCS3-VEGFC) associated with
5 unique brain proteins. Outermost numbers denote chromosomes. Lines link the genomic location of this locus with
genes encoding significantly associated proteins. Associations denote genome-wide significance. Line thickness is
proportional to effect size of linear regression (red, positive; blue, negative).

Several published studies on eQTLs and pQTLs have not identified pleiotropic loci as they only
analyzed cis-associations47,59,76,77. Our results indicate that one protein is regulated along with
different proteins, which are likely part of the same signaling pathway. To understand the
biological processes of health and disease, it is important to identify which proteins are regulated
by the same genetic factors. This study identifies potential tissue-specific pleiotropic effects
highlighting the complex mechanisms that regulate protein levels. Identification of additional
tissue-specific cis-, trans-, and pleiotropic regions will lead to discovery of novel pathways
relevant to pathogenesis.
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Figure3.4 Global view of pleiotropic regions. Unique non-overlapping regions associated with a given SOMAmer
were first defined as 1-Mb region upstream and downstream of each significant variant for that SOMAmer. Within
the region (2Mb) containing the variant with the smallest P value, any overlapping regions were then merged into
the same locus. Next, an LD-based clumping approach was adapted to identify whether a region was associated
with multiple SOMAmers. Variants were combined into a single region per LD (EUR) defined loci. Any loci
associated with more than one protein were identified as pleiotropic regions. Genomic locations of pQTLs were
visualized by a squared-Manhattan plot per tissue. Dark-green represents cis-pQTLs; gold represents trans-pQTLs.
X-axis indicates the positions of the top variant; and Y-axes indicates the gene encoding the protein. All pleiotropic
genomic regions are annotated at the top of each plot along the X-axis. (a) In total, 59 Pleiotropic regions passing
genome-wide significance threshold (5×10-8) in CSF (sample size = 835). (b) In total, 34 pleiotropic regions passing
genome-wide significance threshold (5×10-8) in plasma (sample size = 529). (c) In total, 10 pleiotropic regions
passing genome-wide significance threshold (5×10-8) in brain (sample size = 380).

3.4 Conclusions
In this aim, I first identified tens of independent local pQTLs within each tissue. Next, I
uncovered 10 to 59 pleiotropic regions, depending on tissues, associated with at least two
proteins.
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For identification of conditionally independent local pQTLs, I used the genome-wide
significance for all rounds of conditional analyses. This Bonferroni-based threshold may be too
stringent compared to other multiple testing correction approach, such as false discovery rate.
Given the number of proteins and number of tissues we tested, however, the genome-wide
significance threshold was more feasible for this scale of pQTL datasets.
For identification of pleiotropic region, I first replicated the known pleiotropy of the ABO locus
associated with plasma E-Selectin, as highlighted in Deming et al32 from our lab in 2016 with a
different proteomic profiling platform (RBM). I next extended the framework into a broader
scale for identifying other pleiotropic regions in CSF and brain, reported by other groups in
blood24,25,27.
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4.1 Introduction
The tissue specificity of eQTLs has been widely studied. GTEx consortium20,21 reported that
trans-eQTL tend to be more tissue specific than cis-eQTLs. Lude Franke’s group performed two
meta-analysis studies45,46 of a much larger sample size in blood45 and brain46 uncovered tissuespecific eQTLs only in one of both tissues. It would be important to investigate the tissuespecificity of pQTL with multiple tissues.
Genetic colocalization on pQTL and other molecular traits may help elucidate the missing
heritability of genetic architecture explained by protein level. Multiple molecular trait QTLs
have been published within the recent five years: eQTL by GTEx21 and eQTLgen45,78
consortium; sQTL by GTEx21 consortium; DNA-methylation-QTLs by ROSMAP79 cohort;
histone-acetylation-QTLs by ROSMAP79 cohort. Here, I colocalized pQTLs from WashU
cohort within each tissue to each of these molecular trait QTLs.

4.2 Materials and methods
4.2.1 Identification of tissue-specific/shared pQTLs
I first performed Multivariate Adaptive Shrinkage in R (mashr80) analyses on our multi-tissue
pQTL results given 411 proteins shared by all tissues from the Washington University dataset. I
defined the tissue-specificity as a local false sign rate (LFSR) < 0.05 [LFSR is analogous to a
false discovery rate] and Z-score to be at least 2-fold difference.
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4.2.2 Colocalization analyses
I performed colocalization analysis using the coloc.abf function from the coloc R package81,82
v3.1. I used the default priors with p1= 1×10-4, p2 = 1×10-4, and p12 = 1×10-5. Evidence for
colocalization was assessed using the posterior probability (PP) for hypothesis 4 (indicating that
there is an association for both protein and disease and that they are driven by the same causal
variant(s)). I used PP.H4 > 0.8 as a threshold to suggest that associations were highly likely to
colocalize.

For colocalization of cis-pQTLs with cis-eQTLs, cis-sQTLs from GTEx v8 release: I downloaded
and used the significant cis-eQTLs and cis-sQTLs summary statistics for two single tissues,
cortex and whole blood, from GTEx65 (https://gtexportal.org/home/datasets). For cis-sQTLs I
used gene-level sQTL results, rather than exon-level sQTLs.
For colocalization analysis of plasma pQTLs with eQTLs from eQTLgen: I downloaded and used
the significant cis- and trans-eQTL summary statistics for blood, from eQTLgen78
(https://www.eqtlgen.org/index.html). In both cases I analyzed cis- and trans-QTLs.
For colocalization of cis-pQTLs with cis-DNA-methylation-QTLs, cis-histone-acetylation-QTLs
from ROSMAP: I downloaded and used the significant cis-DNA-methylation-QTL summary
statistics for brain tissue, from ROSMAP79 (http://mostafavilab.stat.ubc.ca/xQTLServe/). I
downloaded the significant cis-histone-acetylation-QTL summary statistics (assigning to up to
10Mb upstream of the transcription start site given the same gene) for brain tissue, from
ROSMAP79 as well. To ensure that DNA-methylation-QTLs affecting pQTLs are mediated by
eQTLs, I further subset the DNA-methylation-QTLs-pQTLs colocalization result with eQTLspQTLs colocalization result.
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4.3 Results
4.3.1 Tissue-specificity investigation
a) Tissue specificity analysis using both effect size and p-value as input
Our unique study design, which included protein measurements in multiple tissues linked to
genetic data, enables us to investigate the overlap of the genetic architecture of protein levels
across tissues. To identify tissue specificity, I performed mashr80 analyses on my multi-tissue
pQTL results using a p-value threshold of < 0.05 with proteins (n=411) that passed QC in all
three tissues (Figure4.1a). Given a LFSR < 0.05 and Z-score of at least a 2-fold difference, I
found that 15 to 26% of cis-pQTLs were tissue specific (Figure4.1b) while 77 to 91% of transpQTLs were tissue specific (Figure4.1c). This analysis indicated that cis-pQTLs were more
likely to be shared across tissues than trans-pQTLs. For example, SIG14 only had a cis-pQTL
shared across all three tissues. I performed additional analyses by comparing the proportion of
pQTLs shared across tissues with different p-value thresholds, reaching the same conclusion.
CSF and plasma each share more than 70% of brain pQTLs, suggesting that CSF and plasma are
informative tissues for studying brain-related disorders such as AD.
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Figure4.1 Summary of the tissue-specificity analyses. (a) Venn diagrams of proteins passing QC across all three
tissues. (b) Bar plot of tissue specificity percentage inferred from mashr on all cis-pQTLs across all three tissues
given p-value < 0.05 threshold. (c) Bar plot of tissue specificity percentage inferred from mashr on all trans-pQTLs
across all three tissues given p-value < 0.05 threshold.

b) Tissue specificity analysis using only the p-value as input
I compared the overlap of genome-wide significant cis and trans-pQTL between CSF, plasma
and brain, while focusing on the proteins (n=411) that passed QC in all three tissues. I observed
that cis-pQTL are more likely to be shared across tissues than trans-pQTL. When using the
standard genome-wide significance cutoff as a threshold, I found that 11.8% (21 of 199) of cispQTL loci were shared between the three tissues, and 48% (86/178) of cis-pQTL are found in
two or more tissues. Although cis-pQTL are often shared between tissues, more than half of the
pQTL (92/178) were tissue-specific. Only one trans-pQTL was shared across all tissues and only
14.0% (19 of 135 trans) are shared between two or more tissues. Plasma shared more pQTL with
CSF than brain; in cis: 72 vs 24; and trans:19 vs 1 (Figure4.2a). CSF seems to capture the
overall genetic architecture of brain protein levels better than plasma, as 91% (32/35) of the brain
cis-pQTL are found in CSF compared to the 68% (24/35) captured by plasma.
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Figure4.2 Tissue specificity exploration with permissive thresholds. To determine whether our tissue-specificity
results were biased by statistical power, we performed similar analyses with two more permissive p-values on the
411 proteins. (a) Venn diagrams of all pQTLs across all three tissues by fixing genome-wide significance threshold
(5×10-8) for all three tissues. (b) Venn diagrams of all pQTLs across all three tissues by fixing genome-wide
significance threshold for one tissue and 0.001 for the other two tissues. For example, when checking CSF pQTLs
shared in plasma or brain, we chose 5×10-8 as threshold for CSF and 0.001 for plasma or brain. (c) Venn diagrams
of all pQTLs across all three tissues by fixing genome-wide significance threshold for one tissue and 0.05 for the
other two tissues. For example, when checking CSF pQTLs shared in plasma or brain, we chose 5×10 -8 as threshold
for CSF and 0.05 for plasma or brain.
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As our sample size was not consistent across tissues and CSF had a higher number of samples,
these results could be biased by differential statistical power. Therefore, I performed similar
analyses with more permissive p-values. I contemplated two complementary scenarios: a pQTL
is shared across tissues if it is genome-wide significant for one tissue and has a p-value of <0.001
or p<0.05 (Figure4.2b,c). These two scenarios led to similar results as those performed with the
genome-wide threshold. Between 22 to 32% of the cis-pQTL were found in all the tissues
compared to 2 to 4% of the trans-pQTL, and CSF was able to capture most of the cis and trans
brain pQTL. I performed similar comparisons by comparing our CSF and brain pQTL with the
plasma pQTL from the INTERVAL study25 that includes 3,301 samples to confirm that my
findings were not an artifact of the sample size. For these comparisons, I focused on 616 proteins
that passed QC in CSF and brain from this study, and plasma from INTERVAL study25
(Figure4.3a-d).
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Figure4.3 Tissue specificity exploration with plasma result from INTERVAL study. To further demonstrate
that tissue-specificity findings are not a product of different sample size, we performed similar comparisons by
analyzing the plasma pQTLs from the INTERVAL study on 616 proteins that passed QC in our CSF, brain and
plasma INTERVAL. (a) Venn diagrams of proteins passing QC across all three tissues: CSF and brain results are
from WashU cohort, plasma result is from INTERVAL study. (b) Venn diagrams of all pQTLs across all three
tissues by fixing genome-wide significance threshold (5×10-8) for all three tissues. (c) Venn diagrams of all pQTLs
across all three tissues by fixing genome-wide significance threshold for one tissue and 0.001 for the other two
tissues. For example, when checking CSF pQTLs shared in plasma or brain, we chose 5×10 -8 as threshold for CSF
and 0.001 for plasma or brain. (d) Venn diagrams of all pQTLs across all three tissues by fixing genome-wide

71

significance threshold for one tissue and 0.05 for the other two tissues. For example, when checking CSF pQTLs
shared in plasma or brain, we chose 5×10-8 as threshold for CSF and 0.05 for plasma or brain.

4.3.2 Colocalization of pQTLs with other molecular QTLs
eQTL mapping and colocalization analyses have been instrumental to identifying the functional
genes in genetic studies of complex traits65,83. However, it is known that changes in transcript
level do not necessarily translate to changes in protein level. To identify the most likely gene
underlying the GWAS signals, it is vital to go beyond eQTL and use other types of molecular
QTLs. To determine if pQTLs provide additional information to that of eQTLs, I performed
colocalization analyses on pQTLs with eQTLs.
Colocalization analyses indicated that only 13.3 to 33.3% of pQTLs had a posterior probability
of hypothesis-4 (PP.H4)>0.8 for the GTEx cortex eQTLs or 14.2 to 17.5% for GTEx whole
blood eQTLs. These results were further replicated on the much larger study of blood eQTLs
from the eQTLgen78 consortium (N=31,684 samples). In brain, 28% of our pQTLs were
colocalized in GTEx, which is within a similar scale to the Robins et al. (2019) study47 in which
the authors used mass spectrometry-based proteomics to measure 7,901 proteins in 144 samples
(Note, this preprint later became published30 after peer review in 2021 with a sample size of 330
with both AD cases and healthy controls). This may also be explained by the fact that there are
only 323 brain samples in GTEx compared to 380 in this study, which represents the largest
brain pQTL analysis performed so far. In plasma, 16% of our pQTLs colocalized with eQTLs,
similar to previous studies25. No previous studies have analyzed the colocalization between
pQTLs and eQTLs in CSF.
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Although eQTL mapping has been the most common approach to identify the genes underlying
the GWAS signals, there are other types of molecular QTLs (splicing, DNA-methylation, or
histone-acetylation) that could be useful. I also wanted to determine the overlap of pQTLs found
in this study with splicing, DNA-methylation, and histone-acetylation QTLs (Figure4.4).

Figure4.4 Upset plots for colocalization investigation on pQTLs vs xQTLs. Note, xQTLs included expressionQTLs, splicing-QTLs, DNA-methylation-QTLs, histone-acetylation-QTLs for each tissue in cis and the bottom
panel with the percentage of remaining pQTLs not colocalized.

Our colocalization analyses indicated that just 3.1 to 16.7% of pQTLs were splicing-QTLs.
Between 1.03 to 10% of pQTLs colocalized with DNA-methylation QTLs, and fewer than 2%
colocalized with histone-acetylation QTLs. Overall, between 48 (brain) to 76.6% (CSF) of
pQTLs identified in this study did not colocalize with QTLs for expression, splicing, DNA-
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methylation, or histone-acetylation, suggesting that protein level may help explain some missing
heritability of disease when being integrated with other layers of molecular traits.

4.4 Conclusions
In this aim, I identified more tissue-specific pQTLs in trans than in cis within each tissue. I
reported that 48 to 76.6% of pQTLs identified in WashU cohort did not colocalize with
expression, splicing, DNA-methylation, or histone-acetylation QTLs. Tissue specificity
emphasizes the importance to map disease mechanisms in a tissue dependent manner.
Colocalization of genetic control on protein levels with other molecular traits highlights
importance of curating proteins to resolve the missing heritability of complex disease-related
human traits.
Larger scale of eQTLs and sQTLs on brain tissues could help resolve some current missingness
related to neurological and psychiatric diseases. In 2020, Zhang et al84 focused on splicing
quantitative trait loci (sQTLs) in 1,209 samples from 13 human brain regions using GTEx
samples. In 2021, de Klein, Tsai, Vochteloo, Baird et al46 investigated the cis and trans eQTLs
using 8,727 RNA-seq samples from multiple brain-regions from 14 datasets.
There are more layers of molecular traits that could explain a proportion of the missing
heritability on disease endpoints within the last two years. In 2019, Liu et al85 published a study
on Circular RNA (circRNA) QTLs (circQTLs) in 589 human dorsolateral prefrontal cortex
samples from CommonMind Consortium. In 2020, Zhang and Luo et al86 reported N6methyladenosine (m6A)-QTLs using 60 Yoruba lymphoblast cell lines. This year, 2021, Xiong
and Hou et al87 identified the same type of QTL but using 4 human tissues (brain, lung, heart,
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and muscle) from 91 donors collected by GTEx consortium. Also using samples from GTEx
consortium and in the same year, Li and Huang et al88, however, built a 46-tissue atlas of 3′UTR
alternative polyadenylation (APA) quantitative trait loci (3′aQTLs) from 467 donors. Together,
these datasets could be used to facilitate mapping variants to function systematically.
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5.1 Introduction
It would be intriguing to not just show the association of proteins and AD risk or other
neurological traits, but also to infer the protein function in causing AD. Using Mendelian
Randomization (MR), this causality can thus be inferred statistically. From MR framework,
SNP-protein (exposure) effects and SNP-AD risk (outcome) effects can be derived from
independent studies. Using the summary statistics alone, it is feasible to estimate the causal
extent of the exposure on the outcome. This strategy highlights the usage of pre-existed
population-scale GWAS into novel discovery, as the causality between exposure and outcome
don’t need to be measured in the same subject groups.
These findings could prioritize proteins for the functional validation study. It would be costeffective to select proteins showed significant protective/inductive effect on AD risk, not the
proteins caused by AD. Thus, the findings could help identify potential endophenotypes for AD
or other neurological traits.

5.2 Materials and methods
5.2.1 Performing MR using TwoSampleMR R package
Mendelian randomization is a method of using measured variation in genes of known function to
examine the causal effect of a modifiable exposure on disease. This method obtains unbiased
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estimates of the effects of a putative causal variable without conducting a traditional randomized
trial. I used the R package TwoSampleMR v0.4.2237. For single SNP remained after clumping,
the most basic method, the Wald ratio, was used. This package also implements the
harmonization steps before performing MR, and these steps are: 1) Correcting the wrong
effect/non-effect alleles; 2) Correcting the strand issues; 3) Fixing the palindromic SNPs; 4)
Removing the SNPs with incompatible alleles. The SNPs selected for the analysis were the based
on a suggestive threshold of 1×10-5. The beta-coefficients and standard errors (SEs) for the
selected variants (pQTL) from this study were used as input of instrumental variables. These
instrumental variables were also extracted from the summary statistics from the latest GWAS for
the outcome on neurological disease related traits. (Briefly, AD-risk GWAS was published in
201919; AD-progression GWAS in 201889; AD-age at onset GWAS in 201790; PD-risk GWAS in
201991; ALS-risk GWAS in 201692; FTD-risk GWAS in 201493; Stroke-risk GWAS in 201894,
Table 4.1). To test the directionality of exposure causing outcome is valid, I used the
directionality_test function from the same R package. The method confirms whether the
exposure (protein) and outcome (trait) directions are correct or not.

5.2.2 Colocalization analyses
I performed colocalization analysis using the coloc.abf function from the coloc R package81,82
v3.1. I used the default priors with p1= 1×10-4, p2 = 1×10-4, and p12 = 1×10-5. Evidence for
colocalization was assessed using the posterior probability (PP) for hypothesis 4 (indicating that
there is an association for both protein and disease and that they are driven by the same causal
variant(s)). I used PP.H4 > 0.8 as a threshold to suggest that associations were highly likely to
colocalize.
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For colocalization of pQTLs with disease status: I downloaded and used the full GWAS
summary statistics for each disease/trait from their original publications as the same for MR
analysis.

5.2.3 Overlap of proteins with pQTLs and drug targets
To obtain information on drugs that target proteins with pQTLs from this study, I used the
DrugBank database (as of 1/3/2020)95. This is a manually curated database that maintains
profiles for >15,000 drugs (including FDA-approved and experimental drugs). For my analysis, I
focused on the protein as target for each drug. For each protein assayed, I identified all drugs in
the DrugBank with a matching protein target based on UniProt ID, annotated via
https://www.uniprot.org/database/DB-0019. I further integrated the MR results on proteins that
can be used as drug targets.

5.3 Results
As a large proportion of pQTLs are not eQTLs or other types of QTLs, it is possible that the
pQTLs identified in this study can help to identify the gene explaining GWAS signals. Using the
MR framework, it is possible to identify functional genes and to prioritize proteins involved with
complex traits for further analyses32,96. To identify proteins implicated in AD and other
neurological traits, I performed MR analysis by using pQTLs as instrumental variables and AD
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risk, progression, and onset; Parkinson’s disease (PD); Frontotemporal dementia (FTD);
Amyotrophic lateral sclerosis (ALS); and stroke risk (Table5.1) as outcomes.

Table5.1 Summary of GWAS publication used as outcome trait for MR
Outcome

First author

Publication year

PubMed ID

AD-risk
AD-progression
AD-age at onset
PD-risk
ALS-risk
FTD-risk
Stroke-risk

Kunkle
Del-Aguila
Huang
Nalls
van Rheenen
Ferrari
Malik

2019
2018
2017
2019
2016
2014
2018

30820047
29480181
28628103
31701892
27455348
24943344
29531354

Only pQTLs with an F-statistic 10 were included, and all pleotropic regions identified in this
study were excluded. After multiple testing correction, I identified three proteins involved in AD
risk in CSF, 13 in plasma, and 7 in brain. Other proteins found to be implicated in other traits by
MR can be found in Table5.2, Figure5.1. The Steiger test was used to confirm the direction of
inference from protein to trait.

Table5.2 Number of significant protein-trait associations from MR analyses
Outcome
CSF
Plasma
Brain
AD risk
3
13
7
AD progression
18
25
6
AD Age at Onset
8
2
20
PD risk
13
15
35
ALS risk
1
4
3
FTD risk
1
8
5
Stroke risk
7
8
24
Within each tissue, the table contains the number of significant proteins (FDR < 0.05/24) and associations with the
seven neurological traits: 1) AD risk 19; 2) AD progression 89; 3) AD Age At Onset 90; 4) PD risk 91; 5) ALS risk92;
6) FTD risk 93; 7) Stroke risk94.
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Figure5.1 Mendelian randomization prioritized proteins in the associated relationship with seven
neurological traits. MR results were calculated using the TwoSampleMR R package37, and the effects for each
protein-disease pair are visualized using Heatmap of MR inference of (a) CSF, (b) plasma, and (c) brain protein
effect on seven neurological-related traits. The p-value threshold for significance is 0.05 after multiple testing
correction accounting for both tissues and diseases. The color represents whether the effect size is positive (yellow)
or negative (blue). Alzheimer disease (AD); Parkinson’s disease (PD); Amyotrophic lateral sclerosis (ALS);
Frontotemporal dementia (FTD). Stroke is the general risk, not a specific subset of the stroke. The asterisk sign*
represents colocalization with a PP.H4 > 0.8 for the protein-disease pair.

Colocalization provides additional supporting evidence of inference by reducing the possibility
that linkage disequilibrium (LD) has influenced MR findings41. I found that 42.5% of proteindisease associations colocalized with GWAS loci, including plasma Siglec-3 (also known as
CD33) and AD risk (Table5.3).
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Table5.3 Summary of MR and colocalization [PP.H4 > 0.8] result for protein and trait associations in three
tissues
CSF_MR
PLASMA_MR
BRAIN_MR
disease/trait_type
+Coloc
+Coloc
+Coloc
AD-risk
1
11
6
AD-progression
4
3
0
AD-age at onset
4
1
3
PD-risk
10
12
19
ALS-risk
0
2
0
FTD-risk
1
6
1
Stroke-risk
6
6
0
OVERALL_rate_mergeMRandColoc
0.51
0.547
0.29

Integrating MR results (using cis- and trans-pQTLs as instrumental variables) with data from
drug databases can be used to repurpose known drugs for diseases without treatment. In this
study, I identified 25 drugs (Table5.4) that are known to interact with proteins that were
identified by MR as being associated with AD, PD, ALS, or stroke.

Table5.4 Summary statistics of drug target overlap of proteins with pQTL and integrating with
Mendelian Randomization result
Target
DrugName
outcome
tissue
sLeptin R
Leptin
PD_risk
t1_CSF
7-AMINO-4-METHYLCyclophilin F
CHROMEN-2-ONE
STROKE_risk
t1_CSF
PolyUbiquitin K63
N-Formylmethionine
AD_progression
t1_CSF
Layilin
Hyaluronic acid
PD_risk
t1_CSF
Carbonic Anhydrase IV
Acetazolamide
ALS_risk
t1_CSF
(3R)-METHYLCARBAMOYL-7SULFOAMINO-3,4-DIHYDRO1H-ISOQUINOLINE-2CARBOXYLIC ACID BENZYL
PTP-1B
ESTER
AD_risk
t1_CSF
phosphoglycerate kinase 1
3-phospho-D-glyceric acid
PD_risk
t1_CSF
PSME1
Copper
AD_progression
t1_CSF
Siglec-3
AVE9633
AD_risk
t1_CSF
Endothelin-converting enzyme 1 5-(2-hydroxyethyl)nonane-1,9-diol AD_progression
t1_CSF
ASAHL
Cannabidiol
PD_risk
t1_CSF
C4b
Human immunoglobulin G
AD_aao
t1_CSF
sE-Selectin
Carvedilol
AD_progression
t1_CSF
MMP-12
(1S,5S,7R)-N~7~-(BIPHENYL-4STROKE_risk
t2_plasma
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Coagulation Factor XI
S100A12
PSME1
Siglec-3
VEGF sR3
IDUA
sE-Selectin

VEGF sR2
PGM1
PPAC
Cathepsin B
IDE
CPNE1
C4b
GPNMB

YLMETHYL)-N~3~-HYDROXY6,8-DIOXA-3AZABICYCLO[3.2.1]OCTANE3,7-DICARBOXAMIDE
(1R)-2[(Diaminomethylene)amino]-1-{4[(4R)-4-(hydroxymethyl)-1,3,2dioxaborolan-2-yl]phenyl}ethyl
nicotinate
Amlexanox
Copper
AVE9633
ABT-869
Chondroitin sulfate
Carvedilol
3-(2-aminoquinazolin-6-yl)-1-(3,3dimethylindolin-6-yl)-4methylpyridin-2(1H)-one
Alpha-D-Glucose 1,6Bisphosphate
4-Nitrophenyl Phosphate
2-Aminoethanimidic Acid
Bacitracin
Theophylline
Human immunoglobulin G
Glembatumumab vedotin

AD_progression
PD_risk
AD_aao
AD_risk
STROKE_risk
PD_risk
STROKE_risk

t2_plasma
t2_plasma
t2_plasma
t2_plasma
t2_plasma
t2_plasma
t2_plasma

STROKE_risk

t2_plasma

AD_aao
AD_aao
PD_risk
AD_progression
AD_risk
AD_risk
STROKE_risk

t3_brain
t3_brain
t3_brain
t3_brain
t3_brain
t3_brain
t3_brain

Target is the protein name with both significant MR result and can be used a drug target. DrugName is the name of
drug curated from DrugBank database. Outcome is the disease or trait the protein inferred to be associated with.
Tissue is where the protein was profiled.

Some specific examples of how this data can be leveraged to map additional GWAS loci and
identify drug targets include plasma CD33 for AD risk, plasma IDUA for PD risk, CSF Carbonic
Anhydrase IV for ALS risk, and CSF/plasma E-Selectin for stroke risk. I found that variants in
the CD33 locus, associated with plasma CD33 protein levels, are also known to be associated
with AD risk19. MR analyses indicated that CD33 is implicated in AD. CD33 is a microgliaspecific gene97 and likely affects microglia activity and innate immune response. My analyses
also indicated that CD33 is a target of AVE9633, an anti-CD33 antibody used to treat acute
myeloid leukemia, and therefore this antibody could be used in the context of AD. An ongoing
clinical trial has been using antibodies targeting CD33 as a potential therapy for AD98. In
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summary, this analysis validated CD33 as a key protein to AD; it is also part of the TREM2MS4A4A pathway.
Another example is plasma IDUA for PD risk. The IDUA locus is the third most significant locus
in the largest GWAS91 studying PD risk. This locus contains more than one independent signal
associated with PD91 and it was unclear which gene was functional. I found a SNP at this locus
that is associated with plasma IDUA protein level and PD risk (rs35220088; p= 2.47×10-6 and
3.52×10-9, respectively). The MR and colocalization analyses indicated that IDUA, encoded by
IDUA, is functional (FDR=9.37×10-6; PP.H4 = 0.998). IDUA degrades glycosaminoglycans in
the lysosome. My investigation identified chondroitin sulfate as a drug that could play a role in
the IDUA pathway.
The third example is CSF Carbonic Anhydrase IV for ALS risk., which is supported by MR
analysis (FDR = 7.61×10-6). I further inferred Acetazolamide as a potential drug to treat ALS
risk. Acetazolamide, used to treat glaucoma, epilepsy and altitude sickness, is known to inhibit
carbonic anhydrases99. Moreover, a recent in vitro study100 supported this drug as a potential
treatment for ALS.
The fourth example is CSF or plasma E-Selectin protein. E-Selectin is a known stroke
biomarker75, and my MR plus colocalization analyses indicated that this protein is genetically
associated with the disease. Carvedilol was identified from our drug repositioning analysis and
has been reported to provide neuroprotection in animal models101.
In summary, our study is useful for mapping additional GWAS loci and identifying drug targets.
I integrated my MR results with drug databases to identify potential drugs that could be
repurposed for neurological diseases. It is known that compounds targeting proteins that are
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supported by genetic data are more likely to work than those without such support102. This study
goes beyond AD or PD, and the data generated here can be applied to other traits.

5.4 Conclusions
In this aim, I identified proteins within each tissue in a causal pathway leading or protecting
seven neurological traits.
Some of these proteins were known to be regulated by GWAS hits, but others were novel. For
AD-risk as outcome, Siglec-3 protein (encoded by CD33) was a known modifier of AD risk, and
I observed this protein in CSF and plasma was significantly associated with AD risk. For PDrisk as outcome, IDUA protein was a known PD risk regulator, and I observed this protein in
plasma was significantly positively associated with AD risk. For stroke as outcome, E-Selectin
protein was a known stroke biomarker75, and I observed this protein in CSF and plasma was
significantly associated with stroke risk.
Some proteins were inferred to be functional across more than one neurodegenerative disease
within each tissue. Among CSF proteins, IL-1F6 was in causal pathways of AD-progression,
PD-risk and FTD-risk; SLAF5 was involved into causal pathways of both AD-risk and PD-risk.
Among plasma proteins, MICA was involved into causal pathways of both AD-risk and FTDrisk; PSME1 was involved into causal pathways of both AD-age at onset and PD-risk. Among
brain proteins, APOE was in causal pathways of AD-risk, AD-age at onset and FTD-risk; IL-17
RD was involved into causal pathways of both FTD-risk and stroke-risk; PPAC was involved
into causal pathways of both AD-age at onset and ALS-risk.
Other novel findings are not reported because the outcome has not been explored, such as
progression and age at onset of AD.
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Taken together, these findings prioritized the proteins for the functional validation study. Thus,
the findings helped identify potential biomarkers for AD or other neurological traits.
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6.1 Introduction
Two-sample Mendelian Randomization (MR)37,103, a genetic epidemiological method, has been
increasingly used to infer effect of an exposure on an outcome using genetic variants as
instrumental variables from the summary statistics of the human disease-related phenotypes.
Colocalization approaches82,104,105 have been used to support inference by reducing the likelihood
that linkage disequilibrium (LD) affected MR findings41,43. As proteins are more likely to be
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used as drug target than other molecular traits106,107, MR analyses accompanied with
colocalization using pQTLs as instrumental variables would be valuable for the broad
community of human genetics108. There were multiple MR studies inferring effects of proteins
on diseases, but most of them focused on fewer than 10 diseases38,40,41,109.
In 2020, Zheng and colleagues43 performed a study of phenome-wide two-sample MR and
colocalization on over 200 phenotypes (diseases/risk factors) using 1,002 proteins from five
large-scale plasma pQTL datasets. A similar proteome-by-phenome-wide MR study was
performed by Bretherick and colleagues44 using 64 plasma pQTLs as instrumental variables.
However, these two studies were based exclusively on plasma proteomics, limiting its
application to other disease-relevant tissues110, such as brain when investigating psychiatric or
neurological diseases or CSF when investigating neuro-immune related disorders. In our
previous study111 we demonstrated that pQTLs (~20% cis pQTLs; ~80% trans pQTLs) are tissuespecific. Therefore, by leveraging pQTL datasets from other tissues, it would be possible to
identify tissue-relevant MR-prioritized proteins and potential drugs.
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Figure6.1 Schematics of the study design of phenome-wide proteome MR. (A) Instrumental variables were
selected from multi-tissue pQTL datasets and used for performing Mendelian randomization with 211 phenotypes.
(B) Details on total numbers of proteins with instrumental variables included in this study within each tissue.

In the same study, we identified hundreds of novel and known CSF, plasma and brain pQTLs
that were further used to identify proteins and drugs implicated in neurological-centric diseases
(Alzheimer disease (AD), Parkinson’s disease (PD), frontotemporal dementia (FTD),
amyotrophic lateral sclerosis (ALS) and stroke)111. Here, I leverage this large multi-tissue pQTL
atlas to identify additional MR-prioritized proteins for 211 complex disease-related phenotypes43
(Figure6.1, 6.2), including 37 biological traits, 21 blood traits, 23 cancer types, 18 neurological
diseases, 94 other diseases, 10 personality traits, and eight other risk factors.
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Figure6.2 Flowchart of analyses performed in the study of phenome-wide proteome MR. Overall, eight steps
were implemented in this study: step-1 as outcome selection; step-2 as genetics instrumental variables selection;
step-3 as validation of genetic instrumental variables; step-4 as MR and colocalization analyses with two options:
4a) cis-only instrumental variables passing study-wide significance; 4b) cis and trans instrumental variables passing
genome-wide significance; step-5 as combinations of two options of protein-phenotype associations within each
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tissue; step-6 as cross-tissue comparisons of the same protein-phenotype associations; step-7 as enrichment with
druggable genome; step-8 as drug repositioning.

6.2 Materials and Methods
6.2.1 WashU multi-tissue pQTL summary statistics
The summary statistics for pQTL for three tissues were processed as described in publication of
Yang et al111 and publicly available at The National Institute on Aging Genetics of Alzheimer's
Disease Data Storage Site (NG00102 dataset). In brief, we performed a linear regression on
genotype dosage (additive model) against each protein level measured by an aptamer-based
platform31, including age, sex, first two principal component factors from population
stratification and genotype platforms as covariates. We generated a dataset in three tissues (835
CSF, 529 plasma and 380 brain), by profiling thousands of proteins (713 CSF, 931 plasma and
1079 brain) and 14,059,245 imputed and directly genotyped common variants. CSF samples
were collected the morning after an overnight fast, processed, and stored at -80°C. Plasma
samples were collected the morning after an overnight fast, immediately centrifuged, and stored
at -80°C. Brain tissues were collected from fresh frozen human parietal lobes. Hereafter, I
termed the dataset as Washington University (WashU) cohort111.

6.2.2 Meta-analyses on CSF pQTLs
I performed fixed effect meta-analyses using METAL58 based on inverse-variance weighting.
The studies used for meta-analysis on CSF pQTLs were from Parkinson's Progression Markers
Initiative (PPMI) released in 2019112 (N = 132), and from WashU cohort111.
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6.2.3 Meta-analyses on plasma pQTLs
I performed fixed effect meta-analyses using METAL58 based on inverse-variance weighting.
The studies used for meta-analysis on plasma pQTLs were from INTERVAL cohort25 (N =
3301), and from WashU cohort111.

6.2.4 Human phenotype selection
I focused on the human phenotypes from a prior study43 that aggregated more than 200
phenotypes for MR analyses. The authors selected complex human phenotypes using MR-Base
database37 and using two criteria: 1) The GWAS with the largest sample size given the same
disease with multiple GWAS; 2) GWAS with full summary statistics available as feasible to
perform downstream analyses. Diseases and risk factors were chosen as outcomes. Starting with
225, I found, however, only 211 phenotypes with a valid ID (Figure6.1, 6.2, TableA1) due to
the upgrade for database of MR-Base37 and its accompanied MRC Integrative Epidemiology
Unit (IEU) OpenGWAS project42 since January 2020. The summary statistics for all phenotypes
were downloaded from the IEU OpenGWAS project website as VCF files113 and corresponding
index files for later colocalization usage. We categorized these phenotypes into seven groups: 1)
biological traits, 2) blood traits, 3) cancer, 4) neurological diseases, 5) other diseases and traits,
6) personality traits, and 7) other risk factors. LD score regression114 Version 1.0.1 was used to
calculate the genetic correlations between each pair of the phenotypes.

6.2.5 Instrumental variable selection for MR
Two options (Figure6.2) were used to select instrumental variables: A) cis study-wide
significant pQTL (termed as ‘cis-only’ analysis) after keeping variants associated with fewer
than five proteins, the same threshold from the previous study43 to avoid too many pleiotropic
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effects: the study-wide significance threshold is defined as protein-variant pair with a P-value
below the threshold of (5×10−8/number_PCs). The number of PCs was derived as the minimum
principal component number that cumulatively explain 95% of the total proteomic variance
within each tissue after QC. For proteomics of CSF, plasma and brain tissues, the number of
PCs is 169, 230, and 75, respectively. Thus, the p-value thresholds are 3×10-10, 2×10-10, and
7×10-10, respectively.; B) both cis and trans genome-wide significant pQTL (p-value < 5×10-8),
termed as ‘cis + trans’ analysis after removing highly pleiotropic variants, same as option-A
above. I next performed LD clumping for the instrumental variables with the R package
TwoSampleMR37 v0.5.3 to identify independent pQTLs for each protein. I used a threshold of r2
< 0.001 to exclude dependent pQTLs in the local genetic regions as the default parameter
implemented in clump_data function.

6.2.6 MR analyses using TwoSampleMR R package
I used R package TwoSampleMR37 v0.5.3, which includes two primary methods: For each single
SNP, the most basic way, Wald ratio, was used; For multiple SNPs without pleiotropy, inverse
variance weighted (IVW) estimator was used. This is the simplest way, and it is a meta-analysis
of each Wald ratio for each SNP. The regression is constrained to pass through the origin, thus
leading to a zero-intercept. This package also implements the harmonization steps before
performing MR, and these steps are listed here: 1) correct the wrong effect/non-effect alleles; 2)
correct the strand issues; 3) fix the palindromic SNPs; 4) remove the SNPs with incompatible
alleles.
In our MR analysis, proteins were set as the exposures and 211 complex human phenotypes as
the outcomes (Figure6.1, 6.2, TableA1). Due to some high correlations among some of the
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tested phenotypes and multiple tissues, I used false discovery rate (FDR) < 0.05 as our multipletest correction approach. The MR results were plotted as heatmaps using geom_tile function
from the R package ggplot261. Miami plots for the cis-only analysis using geom_point function
from the R package ggplot261.

6.2.7 Colocalization analyses on exposure with outcome
To remove the LD bias in MR analyses, I performed colocalization analysis using coloc.abf
function from R package coloc82 v3.1. I first downloaded the full GWAS summary statistics for
each disease/risk factor from the IEU OpenGWAS project42 as VCF files113. I next used the
default priors, with p1 as 1×10-4, p2 as 1×10-4 and p12 as 1×10-5. Evidence for colocalization
was assessed using the posterior probability (PP) for hypothesis 4 (indicating there is an
association for both protein and disease and they are driven by the same causal variant(s)). I
used PP.H4 > 80% as a threshold to suggest that associations were strongly to. I set the window
size to +/- 500kb centering on instrumental variable per protein-phenotype pair. If there were
multiple instrumental variables, I calculated the average PP.H4.

6.2.8 Steiger test on inference direction from exposure to outcome
To mitigate the potential impact of reverse association (that is, the protein as outcome and
phenotype as exposure), I used the Steiger filtering approach to identify the correct directions of
inference (that is, the protein as exposure and phenotype as outcome). Only the proteinphenotype pairs with the correct direction were kept. Specifically, I used steiger_test function
implemented in R package TwoSampleMR37 v0.5.3.
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6.2.9 Replication strategy for protein-phenotype associations
To replicate the protein-phenotype associations in this study, I used the full MR results from the
previous plasma proteome-by-phenome-wide study43. Specifically, I extracted the full MR
results on all protein-phenotype associations using pqtl function implemented in R package
epigraphdb115 v0.2.

6.2.10 Enrichment of proteome-wide MR with the druggable genome
Finan and colleagues116 used targets of first-in-class drugs licensed since 2005; the targets of
drugs currently in late-phase clinical development; information on the preclinical phase small
molecules with protein binding measurements reported in the ChEMBL database117; as well as
genes encoding secreted or plasma membrane proteins that form potential targets of monoclonal
antibodies and other biotherapeutics. The authors identified 4,479 genes as the latest druggable
genome set and further classified these genes into three tiers: Tier-1 contained 1,427 genes
encoding targets of approved small molecules, biotherapeutic drugs and clinical-phase drug
candidates. Tier-2 included 682 genes encoding targets with known bioactive drug-like smallmolecule binding partners and with over 50% identity with drug targets. Tier-3 (3A and 3B) had
2,370 genes encoding secreted or extracellular proteins, more distantly similar proteins to
approved drug targets, and proteins within key druggable gene families not already included in
the first two tiers.
I overlapped the 969 all possible proteins passing QC with the 4,479 genes (all three tiers) from
the druggable genome using the Ensembl gene ID of the encoding genes.
I further assessed the overlap based on whether the protein was used in MR with cis or trans
instrumental variables and based on the druggable genome tiers. Similar to the previous study43
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using plasma pQTLs, I also assessed the enrichment of top pQTL MR findings with the
druggable genome.
In CSF, I used 102 protein–phenotype associations (53 proteins on 54 phenotypes) with both MR
and colocalization evidence. I grouped the 53 proteins into four tiers based on their druggability:
tier-1 contained 14 proteins, tier-2 contained one protein, tier-3 contained 32 proteins and tier-4
contained six proteins as unclassified. The 54 phenotypes were stratified into six groups: 15
biological traits, 11 blood traits, 10 cancer types, one personality trait, one neurological disease,
and 16 non-neurological diseases.
In plasma, I used 96 protein–phenotype associations (40 proteins on 47 phenotypes) with both
MR and colocalization evidence. I grouped the 40 proteins into four tiers based on their
druggability: tier-1 contained eight proteins, tier-2 contained five proteins, tier-3 contained 20
proteins and tier-4 contained seven proteins as unclassified. The 47 phenotypes were stratified
into six groups: 12 biological traits, eight blood traits, seven cancer types, one personality trait,
three neurological diseases, and 16 non-neurological diseases.
In brain, I used 12 protein–phenotype associations (five proteins on 12 phenotypes) with both
MR and colocalization evidence. I grouped the five proteins into four tiers based on their
druggability: tier-1 did not contain any proteins, tier-2 contained one protein, tier-3 contained
two proteins and tier-4 contained two proteins as unclassified. The 12 phenotypes were stratified
into four groups: three biological traits, two blood traits, one cancer type, and six nonneurological diseases.
The protein–phenotype associations with MR and colocalization evidence of each tissue were
colored coded per their four corresponding druggability tiers.
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6.2.11 Drug target repurposing
To obtain information on drugs that target proteins with pQTL from this study, I used the
DrugBank95 database (as of 1/3/2020). This is a manually curated database that maintains
profiles for >15,000 drugs. For our analysis, I focused on the protein target for each drug. For
each protein assayed, I identified all drugs in the DrugBank with a matching protein target based
on UniProt ID54. I further integrated the MR and colocalization results on protein-phenotype
associations into the overlap of proteins as drug targets.

6.3 Results
6.3.1 Inferring multi-tissue protein effects on disease-related phenotypes using
cis study-wide significant pQTLs as instrumental variables
I initially inferred CSF, plasma, brain protein effects on disease or risk factors using two-sample
MR with the cis pQTLs that passed the study-wide significance threshold (120, 55, 20 studywide significant cis protein-locus pairs in CSF, plasma, and brain, respectively). Horizontal
pleiotropy can lead to false positive results in the MR analyses. Although, it is known that cis
pQTLs are less likely to be susceptible to horizontal pleiotropy than trans pQTLs43,103,107, I
removed pleiotropic cis pQTL as instrumental variables (associated with five or more proteins).
We could not use MR-Egger118 or MR-PRESSO119 to correct for horizontal pleiotropy as most of
the proteins were only associated with one valid instrumental variable (F 10) after clumping. I
also performed colocalization analyses to examine the confounding effect by linkage
disequilibrium (LD). Colocalization can provide complementary supporting evidence of
inference by decreasing the likelihood that LD has affected MR findings. Furthermore, I used
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the Steiger test to identify the correct directions of inference. I kept only protein-phenotype pairs
that protein has effects on phenotype thereafter.

Figure6.3 Significant protein-phenotype associations identified using cis-only study-wide pQTLs as
instrumental variables. Heatmaps were generated using the analyses on WashU cohort only. (A) 22 proteins
against 29 diseases in CSF; (B) 11 proteins against 13 diseases in plasma; (C) 5 proteins against 12 diseases in brain.
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Colors were coded by 6 bins after cutting z-normalized beta MR estimate: below -10 as darkblue; -10 to -5 as
dodgerblue; -5 to 0 as cadetblue1; 0 to 5 as antiquewhite1; 5 to 10 as gold; above 10 as orange. Phenotype
categories were listed on the left side as a bar-plot (biological traits as red, blood traits as orange, cancers as purple,
other diseases as green, neurological diseases as blue).

I found that 22 CSF proteins were associated with 29 phenotypes, (26 novel associations;
Figure6.3A, 6.4A, Table6.1) with both significant MR results (FDR < 0.05) and strong
colocalization evidence (PP > 80%); 11 plasma proteins were associated with 13 phenotypes
(one novel association; Figure6.3B, 6.4B, Table6.1); and five brain proteins were associated
with 12 phenotypes (one novel association; Figure6.3C, 6.4C, Table6.1).
Table6.1 Summary table of protein-phenotype pairs from MR results with study-wide cis pQTLs with
WashU cohort, replicated using Zheng et al 2020 full MR results in plasma
Tissue

Total

Replicated

Not replicated

Not found

CSF

48

14

8

26

Plasma

15

12

2

1

Brain

12

11

0

1

Replicated: p-value < 0.05 & the same direction of effect size in the prior plasma study; Not-replicated: p-value >=
0.05 and/or the opposite direction of effect size in the prior plasma study; Not-found: protein-phenotype pairs not
found in the prior plasma study.
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Figure6.4 Miami plots for the cis-only study-wide pQTLs as instrumental variables for all MR and
colocalization analyses on WashU cohort only. Each dot represents the MR results for proteins on human
phenotypes. A) CSF; B) plasma; C) brain. Phenotype categories were color-coded: biological traits as red, blood
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traits as orange, cancers as purple, other diseases as green, neurological diseases as blue; for protein-phenotype
associations not significant or not colocalized, the color is gray.

Among all these protein-phenotype associations, I replicated findings reported in plasma from
previous studies43,115 (Table6.1). In plasma, 10 proteins on 10 phenotypes that were classified
into four unique groups: six biological traits, one cancer type, one neurological disease, and two
other diseases. Some of our findings based on the CSF or brain pQTL datasets were also reported
before in plasma: 11 phenotype associations with eight CSF proteins (four biological traits, two
blood traits, one cancer type, and four non-neurological diseases), and 11 associations with four
brain proteins (three biological traits, two blood traits, one cancer type, and five non-neurological
diseases).
However, I was unable to replicate a few findings reported in the previous study that used
plasma pQTL as instrumental variables because the instrumental variables in our study were not
as strong as in plasma43. In the previous study, plasma Coagulation Factor XI was associated
with two disease-related phenotypes using two instrumental variables (one cis and one trans),
however, here I only used cis-pQTL in this analysis, so I was not able to replicate that finding.
At the same time, the previous study linked six proteins (Table6.1), with seven phenotypes
(three different groups: three biological traits, three blood traits, and one non-neurological
disease). Although I found the pQTLs for those proteins in CSF, not in plasma, our MR analyses
did not identify any associations with those phenotypes.
On the other hand, I uncovered novel protein-phenotype associations (Table6.1). Our analyses
indicate that the CSF protein levels are implicated in or causal to six biological traits (caudate
volume, enzymatic creatinine in urine, diastolic blood pressure, forced expiratory volume in 1101

second (FEV1), forced vital capacity (FVC), years of schooling), three cancer types (ER- Breast
cancer, invasive mucinous ovarian cancer, pancreatic cancer), and nine diseases (asthma,
primary sclerosing cholangitis, Crohn's disease, inflammatory bowel disease, ulcerative colitis,
systemic lupus erythematosus, rheumatoid arthritis, hypothyroidism, and chronic kidney
disease), respectively. One plasma protein (CPNE1) was positively associated with a blood trait
(Hemoglobin concentration) and one brain protein (IDUA) was positively associated with a
disease-related phenotype (celiac disease).
Furthermore, to increase the power of our analyses, I performed two-sample MR using summary
statistics from meta-analyses for CSF (Parkinson's Progression Markers Initiative released in
2019112 and WashU cohort111) and plasma pQTLs (INTERVAL cohort25 and WashU cohort111).
These meta-analyses yielded 10 additional CSF and 125 plasma pQTLs. I found three additional
CSF proteins associated with four phenotypes (two biological traits, one neurological disease and
one non-neurological disease) (Figure6.5A) with significant MR results (FDR < 0.05) and
strong colocalization evidence (PP > 80%). Our analyses also led to the identification of five
additional plasma proteins associated with five phenotypes (two biological traits, one blood trait
and two non-neurological diseases (Figure6.5B). I replicated the associations of CSF CD33
protein with Alzheimer Disease, and three plasma proteins with three different phenotypes (ART
with sodium in urine; B7-H2 with rheumatoid arthritis; Haptoglobin (mixed-type) with increased
height43). I did not replicate three findings due to the weaker instrumental variables compared to
the prior plasma study43. On the other hand, I found two more novel associations not reported in
the previous study: lower CSF CBPE was associated with higher FVC, whereas higher plasma
IL-1 R4 was associated with higher celiac disease risk.
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Figure6.5 Additional significant protein-phenotype associations identified using cis only study-wide pQTLs as
instrumental variables after meta-analyses. Heatmaps were generated using the results of meta-analyses. (A) 3
proteins against 4 diseases in CSF; (B) 5 proteins against 5 diseases in plasma. Colors were coded by 3 bins after
cutting z-normalized beta MR estimate: -5 to 0 as cadetblue1; 0 to 5 as antiquewhite1; 5 to 10 as gold.

6.3.2 Inferring multi-tissue protein effects on disease-related phenotypes using
both cis and trans genome-wide significant pQTLs as instrumental variables
In the previous section, I only used pQTLs that passed the most stringent study-wide threshold.
This threshold, however, may miss the real signals. Therefore, a lower threshold could reveal
additional signals. To increase the power of MR analyses, I expanded our MR analyses by
including potentially non-pleiotropic cis and trans pQTL as instrumental variables (p < 5×10-8,
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F 10 and associated with fewer than 5 proteins). With this threshold, I used 215, 146, 66
genome-wide significant cis and trans pQTLs in CSF, plasma, and brain, respectively, to perform
MR analyses. In total, 40 CSF proteins were associated with 52 phenotypes (Figure6.6A,
Table6.2) with significant MR results (FDR < 0.05) and strong colocalization evidence (PP >
80%); 33 plasma proteins were associated with 44 phenotypes (Figure6.6B, Table6.2); and five
brain proteins were associated with 12 phenotypes (Figure6.6C, Table6.2). Among all these
protein-phenotype associations, I replicated findings reported in plasma before43,115; including 16
plasma proteins on 15 phenotypes, 11 CSF and four brain proteins on 16 and 11 phenotypes,
respectively.
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Figure6.6 Significant protein-phenotype associations identified using cis and trans genome-wide pQTLs as
instrumental variables. Heatmaps were generated using the analyses on WashU cohort only. (A) 40 proteins
against 52 diseases in CSF; (B) 33 proteins against 44 diseases in plasma; (C) 5 proteins against 12 diseases in brain.
Colors were coded by 6 bins after cutting z-normalized beta MR estimate: below -10 as darkblue; -10 to -5 as
dodgerblue; -5 to 0 as cadetblue1; 0 to 5 as antiquewhite1; 5 to 10 as gold; above 10 as orange. Phenotype
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categories were listed on the left side as a bar-plot (biological traits as red, blood traits as orange, cancers as purple,
other diseases as green, neurological diseases as blue, personality traits as pink).

Similar to the cis-only-pQTL analyses above, several protein-phenotype associations did not
replicate due to the weaker instrumental variables (Table6.2) compared to the prior plasma
study43. These included eight plasma proteins and 21 phenotypes (six biological traits, five
blood traits, four cancer types, and six non-neurological diseases); 11 CSF proteins and 11
phenotypes (two biological traits, four blood traits, two cancer types, and three non-neurological
diseases).
Table6.2 Summary table of protein-phenotype pairs from MR results with genome-wide cis and trans pQTLs
with WashU cohort, replicated using Zheng et al 2020 full MR results in plasma
Tissue

Total

Replicated

Not replicated

Not found

CSF

88

19

13

56

Plasma

88

18

31

39

Brain

12

11

0

1

Replicated: p-value < 0.05 & the same direction of effect size in the prior plasma study; Not-replicated: p-value >=
0.05 and/or the opposite direction of effect size in the prior plasma study; Not-found: protein-phenotype pairs not
found in the prior plasma study.

Additional novel protein-phenotype associations were also uncovered when including cis and
trans pQTLs that passed the genome-wide significance threshold. When using CSF pQTL
dataset, Mendelian randomization and colocalization analyses identified proteins linked with 16
biological traits, eight blood traits, seven cancer types, and 25 non-neurological diseases. For
plasma proteins, there were nine biological traits, seven blood traits, five cancer types, one
personality trait, two neurological and 15 non-neurological diseases. One brain protein (IDUA)
was positively associated with celiac disease, the same as MR results using cis pQTLs
(Table6.2).
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Like the previous analyses, I wanted to determine if even more protein-phenotype pairs could be
found by using the pQTLs identified by meta-analyzing the WashU multi-tissue pQTL with
other pQTL summary statistics. By leveraging this meta-analysis strategy, I was able to include
additional 213 CSF and 94 plasma pQTLs, which led to 10 CSF additional proteins associated
with 11 phenotypes (Figure6.7A); and four plasma proteins were associated with four
phenotypes (Figure6.7B). Of these associations, I replicated three associations: one CSF protein
with a neurological disease and the other two plasma proteins each with one biological trait,
respectively. I did not replicate three CSF protein associations with three biological traits.
Additionally, I observed 10 novel protein-phenotype pairs: seven associations (two biological
traits, two blood traits, one personality trait and two non-neurological diseases) with CSF
proteins and two associations (one biological trait and one non-neurological disease) with plasma
proteins.
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Figure6.7 Additional significant protein-phenotype associations identified using cis and trans genome-wide
pQTLs as instrumental variables after meta-analyses. Heatmaps were generated using the results of metaanalyses. (A) 10 proteins against 11 diseases in CSF; (B) 4 proteins against 4 diseases in plasma. Colors were
coded by 4 bins after cutting z-normalized beta MR estimate: -10 to -5 as dodgerblue; -5 to 0 as cadetblue1; 0 to 5 as
antiquewhite1; 5 to 10 as gold.

Of these findings, 27 CSF proteins were associated with 36 phenotypes (Figure6.8A); 24 plasma
proteins were associated with 36 phenotypes (Figure6.8B), which were not identified in our first
analyses using only the study-wide significant cis-pQTLs as instrumental variables. For the 36
phenotypes in associations with CSF proteins, 10 were associated with biological traits, 10 with
blood traits, six cancer types, one personality trait, and nine non-neurological diseases. For
phenotypes associated with plasma proteins, there were eight biological traits, six blood traits,
six cancer types, one personality trait, two neurological diseases, and 13 non-neurological
diseases.
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Figure6.8 Additional significant protein-phenotype associations identified after including cis and trans
genome-wide pQTLs as instrumental variables. Heatmaps were generated using the analyses after meta-analyses.
(A) 27 proteins against 36 diseases in CSF; (B) 24 proteins against 36 diseases in plasma. Colors were coded by 6
bins after cutting z-normalized beta MR estimate: below -10 as darkblue; -10 to -5 as dodgerblue; -5 to 0 as
cadetblue1; 0 to 5 as antiquewhite1; 5 to 10 as gold; above 10 as orange. Phenotype categories were listed on the
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left side as a bar-plot (biological traits as red, blood traits as orange, cancers as purple, other diseases as green,
neurological diseases as blue, personality traits as pink).

6.3.3 Cross-tissue comparisons on tissue consistent and inconsistent proteinphenotype effects
To investigate whether the directions of effects were consistent across tissues given the same
protein-phenotype pairs, I compared the significant MR results (FDR < 0.05) using genome-wide
significant cis and trans pQTLs with strong colocalization evidence (PP > 80%) across three
tissues. I identified 27 pairs in more than one tissue, in which 25 pairs had consistent MR
estimates (Figure6.9). Among these 25 tissue-consistent pairs, 23 were consistent between CSF
and plasma (Figure6.9A,B) and two were consistent between plasma and brain (Figure6.9A,C).
For example, soluble E-Selectin levels consistently correlated with 14 phenotypes CSF and
plasma (Figure6.9A).
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Figure6.9 Cross-tissue MR estimate comparisons. (A) Heatmap were generated on the MR estimates given the
same protein-phenotype pairs with a PP > 80% when performing colocalization. Colors were coded by 6 bins after
cutting z-normalized beta MR estimate: below -10 as darkblue; -10 to -5 as dodgerblue; -5 to 0 as cadetblue1; 0 to 5
as antiquewhite1; 5 to 10 as gold; above 10 as orange. (B) Scatter plots of CSF vs plasma MR estimates on the same
protein-phenotype associations. (C) Scatter plots of plasma vs brain MR estimates on the same protein-phenotype
associations.

Additionally, two pairs showed opposite MR effect sizes (Figure6.9A,B): i) higher CSF ART (or
AGRP, Agouti-related protein) was associated with higher sodium in urine, whereas higher
plasma ART was associated with lower sodium in urine; ii) higher CSF TXD12 was associated
with higher risk of the ER-positive Breast cancer, whereas higher plasma TXD12 was associated
with lower risk of the same phenotype.
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6.3.4 Overlap with druggable genome and drug repurposing
Finally, I overlapped our proteins having strong MR and colocalization evidence with the
druggable genome reported by Finan and colleagues116. To assess the overlap of the proteins
identified in our MR analyses and based on the druggable genome tiers, I performed an
enrichment analysis as described before43. Of the 53 CSF proteins associated with the studied
traits, based on both MR and colocalization, 47 (88.7%) overlapped with the druggable genome
(Figure6.10A). These overlapping CSF proteins were associated with 12 biological traits, nine
blood traits, one personality trait, 10 cancer types, one neurological disease, and 14 nonneurological diseases. Of the 40 plasma proteins associated with studied traits, 33 (82.5%)
overlapped with the druggable genome (Figure6.10B). These overlapping plasma proteins were
associated with seven biological traits, seven blood traits, one personality trait, seven cancer
types, three neurological diseases, and 12 non-neurological diseases. Of the five brain proteins
with both MR and colocalization evidence for associations with the studied traits, three (60%)
overlapped with the druggable genome (Figure6.10C). These overlapping brain proteins were
associated with one biological trait, two blood traits, and five non-neurological diseases.

112

Figure6.10 Enrichment of phenome-wide MR of the CSF, plasma, and brain proteome with the druggable
genome. Heatmap was used to visualize the druggable-genome against categories of phenotypes on proteins with
convincing MR and colocalization evidence, as illustrated by Zheng and colleagues 43. There were seven major
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categories: 1) biological trait, 2) blood trait, 3) cancer, 4) non-neurological disease, 5) neurological disease, 6)
personality trait, and 7) other phenotypes. The Y-axis presents the tiers of the druggable genome (as defined by
Finan and colleagues116) of proteins under analysis in (A) CSF; (B) plasma and (C) brain, with proteins classified
into four groups based on their druggability: tier-1 contains proteins that are efficacy targets of approved small
molecules and biotherapeutic drugs; tier-2 contains proteins closely related to approved drug targets or with
associated drug-like compounds; tier-3 contains proteins distantly related to approved drug targets; and proteins
have unknown druggable status (unclassified). The colored cells denote protein–phenotype associations with
convincing MR and colocalization evidence. Cells in green, yellow, red or purple represent associations with tier-1,
tier-2, tier 3 or unclassified druggable genomes, respectively. The details can be found in Table S15.

Moreover, to prioritize proteins as targets and repurpose the known drugs for the phenotypes, I
linked the MR results using genome-wide significant cis and trans pQTLs with drug databases.
Using the DrugBank95 database which is curated by UniProt54 Knowledgebase (release February
2020), I identified 21, 17, four proteins in CSF, plasma, and brain, respectively, connected with
at least one compound for one disease-related phenotype (Figure6.11).
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Figure6.11 Ranks of proteins by the number of convincing protein-phenotype associations from MR and
colocalization analyses. Bar plots of number of human phenotype (outcome) per protein (exposure). (A) 21 CSF
proteins were ranked and the top protein was sE-Selectin; (B) 17 plasma proteins were ranked and the top protein
was VEGF sR2; (C) 4 brain proteins were ranked and the top protein was FCG2A.
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In CSF (Figure6.12), 28 drugs can be used as an activator given a negative estimate from MR
analyses; and vice-versa, 20 drugs can be used as an inhibitor. In plasma (Figure6.12B), 28
drugs were predicted as activators and 21 as inhibitors; in brain (Figure6.12C), seven drugs were
activators and four as inhibitors. For example, CSF or plasma CD33 can be used as a target of
AVE9633 to treat AD. CSF or plasma E-Selectin can be targeted by Carvedilol to lower the
diastolic blood pressure. Brain FCG2A or CSF FCG2B was found as the same target of
Abciximab and potentially treating systemic lupus erythematosus via findings from MR and
colocalization. CSF vWF can be targeted by PEGylated Antihemophilic Factor (Recombinant), a
biotech drug, to increase the platelet count. CSF or plasma Galectin-3 was found as a target of a
small molecule drug, called 2,3,5,6-Tetrafluoro-4-Methoxy-Benzamide, and potentially reducing
the risk of small vessel disease.
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Figure6.12 Phenotype-drug pairs after integration of protein-phenotype associations from MR and drugprotein interactions from the DrugBank database. Heatmaps were used to visualize drug-name against
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phenotype for the drug target repurposing purpose. The drug predicted effects were listed as follows: (A) in CSF, 28
drugs can be used as an activator given a negative estimate from MR analyses; and vice-versa, 20 drugs can be used
as an inhibitor; (B) 28 activators and 21 inhibitors in plasma; (C) 7 activators and 4 inhibitors in brain. Colors were
coded: activator as magenta; inhibitor as black.

6.4 Conclusions
Here, our study revealed that 40 CSF, 33 plasma, five brain proteins associated with 52, 44, 12
human disease-related phenotypes, respectively. After integrating the existing drug therapies
and published druggable genome results, I found 108 drugs (48 for CSF, 49 for plasma, 11 for
brain) that could be repositioned to treat complex traits.
These results systematically tested the potential effects of proteins, as potential drug targets, on
the human diseases or risk factors by both MR and colocalization in a tissue-specific manner.
92.6% (25 out of 27) of the shared protein effects on phenotypes were consistent across different
tissues, in which 23 were consistent between CSF and plasma and two were consistent between
plasma and brain. No previous studies reported the two opposite associations between CSF and
plasma before on associations of ART with sodium in urine and TXD12 with ER-positive Breast
cancer risk. It has been reported, however, a small proportion of tissue-dependent genetic
variation of gene expression indeed existed. Fu and colleagues120 reported 4.4% eQTLs had
opposite directions using blood and non-blood tissues. Mizuno and Okada121 later performed a
study on the opposite eQTL effects with more tissue types (48 tissues) from Genotype-Tissue
Expression (GTEx) project (release version 7). This later study highlighted that the opposite
eQTL effects can be observed between closely related tissues such as different brain regions (for
example, cerebellum versus brain cortex) and be estimated as 7.4% of the eQTL-genes. These
two studies pinpointed that the opposite genetic effects on gene expression between tissues can
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further contribute to the development of complex traits in a tissue-dependent manner. One latest
study122 published an MR analysis on causal associations between cigarettes per day and multitissue angiotensin-converting enzyme 2 (ACE2) expression. The authors indeed found tissueopposite effects between brain and colon. I extended these observations from gene expression
into protein level.
Our study is the first analysis that systematically evaluated the cross-tissue protein effects on
over 200 phenotypes using pQTLs from three tissues. Our result can be used as a complement
resource to the plasma proteome-by-phenome-wide MR studies43,44. From the MR results using
genome-wide significant pQTLs, we found 56, 39, and one protein-phenotype pairs in CSF,
plasma, and brain respectively, which were not found in the plasma study by Zheng et al43. Our
MR results reveal plasma proteins, as well as CSF and brain proteins, can be prioritized in the
disease pathogenesis and used as a drug target for repositioning. Our study expand the scale of
inferring CSF and brain protein effects on diseases to the phenome-wide scale compared to prior
protein-disease MR studies in CSF40 and brain41. Our results highlight proteins with potential
opportunities for developing treatment with clinical trials, however, further functional
experiments, in vitro and in vivo, would be essential to validate our findings. The proteinphenotype associations with the same tissue-shared effects should be more focused than those
with opposite tissue-specific effects, as tissue-specific drugs can be challenging to develop to
date. The protein-phenotype associations with different tissue-specific effects were inferred by
different instrumental variables, due to the existence of tissue-specific pQTLs.
In our findings (Figure6.11, 6.13), certain protein was associated with multiple phenotypes.
This was because instrumental variable for the same protein was shared across multiple
phenotypes. For example, CSF sE-Selectin was associated with 14 phenotypes in total. The
119

correlation between each phenotype (Figure6.13A) revealed that not all 14 phenotypes are
highly correlated with each other, though some phenotypes were indeed highly correlated, such
as ovarian cancer (ieu-a-1120) and high grade serous ovarian cancer (ieu-a-1121); breast cancer
(ieu-a-1126) and ER-positive breast cancer (ieu-a-1127); coronary heart disease (ieu-a-7) and
myocardial infarction (ieu-a-798); FVC (ukb-a-336) and FEV1 (ukb-a-337). This indicated CSF
sE-Selectin played an important role in multiple diseases with a small proportion of correlations.
Similar observations held true for plasma VEGF sR2 (Figure6.13B) and brain FCG2A
(Figure6.13C).
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Figure6.13 Genetic correlation of phenotypes with top ranked protein from MR and colocalization analyses.
Heatmap was used to visualize the phenotype-phenotype correlation matrix of the top ranked protein within each
tissue: (A) CSF sE-Selectin associated with 14 phenotypes; (B) plasma VEGF sR2 associated with 16 phenotypes;
(C) brain FCG2A associated with 6 phenotypes.
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Our study has several limitations. First, our bulk-tissue proteomic profiling was not cell-typespecific. Thus, our estimation on protein-phenotype would be biased when using cell-typespecific proteomic datasets if available. However, we were accounting for different tissues
compared to the prior single-tissue study43. Second, our pQTL dataset did not capture all human
proteins, thus the findings may not represent the whole genomic atlas of human protein. Third,
the epitope-binding effect instead of true abundance change from aptamer-binding assay would
create artefacts of pQTLs. Fourth, the pleiotropy instrumental variables may still be missing due
to our limited coverage of whole human proteome. Fifth, sensitivity analyses would not be
possible for most QTL studies, as stated by Baird and colleagues123. As an alternative approach,
Burgess and colleagues claimed as a guideline103 that colocalization can help evaluate exposures
such as proteins and gene expression, particularly when the MR result is derived from a singlegene region.
In summary, our work evaluates multi-tissue protein effects on disease-related phenotypes in a
large proteome-by-phenome-wide scale. We anticipate future much larger-scale studies with
more proteins from more tissues and more phenotypes to facilitate the drug repositioning
process.
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Chapter 7: Future directions
7.1 Future of pQTL studies
This thesis sheds light on the future of pQTL studies. First, there are multiple platforms now
with a larger protein pool. For example, SOMAscan now expands to 7k panels as of 1st half of
2021; Olink enlarges to 3,072 proteins coupling with NGS readout instead of prior microarray
format expected in October 2021; Mass-spectrometry techniques can profile over 8,000 unique
proteins after processing the raw peptide datasets.
Second, sample size will be larger. For example, UK Biobank launched the Pharma Proteomics
Project in December 2020 to measure >3,000 blood proteins with the latest Olink platform
(upgraded from 1.5k to 3k in July 2021). This project involved with 10 pharmaceutical
companies, including Biogen, Genentech, Amgen, Bristol Myers Squibb, AstraZeneca,
Regeneron, GSK, Pfizer, Takeda, Janssen. Each company will share resources and maintain
their specific disease cohorts in the study design. There are other ongoing large population-scale
proteomics studies, for example, deCode genetics124, SCALLOP consortium28, TOPMed
program125.
Third, more diverse tissue types can be collected. For example, enhancing GTEx (eGTEx)
consortium126 planned to profile Mass-spectrometry based proteomics from 12 different tissues
(brain, heart, lung, muscle, thyroid, colon, liver, prostate, pancreas, ovary, testis, breast). The
first phase of this plan of multi-tissue proteomics was published recently in late 2020127. I expect
that their multi-tissue pQTL study will be published soon.
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Forth, more diverse ethnicities or population ancestries would be emphasized. For example, a
recent study128 focused on plasma pQTL effect comparisons between European Americans and
African Americans. This opens a new door for including participants from more diverse
populations background in the future, for instance, East Asians, South Asians.
Fifth, cell-type specific proteomics profiling techniques may be developed. High-throughput
single-cell proteomics techniques will be the next challenge after single-cell RNA-seq
technologies exceeds to millions of cells per experiment within the last five years. Currently,
CITE-seq129 can only profile cell-surface proteins in a high-throughput scale, limiting its usage
for non-immunological filed, such as neuroscience. These single-cell datasets will uncover the
cell-type specific pQTLs directly instead of post hoc inferring cell-type enrichment from bulklevel datasets.
Sixth, context-dependent QTLs might be useful to track disease-specific QTLs. Recent eQTL
studies130 suggested that different contexts, such as drug response, may be associated with novel
eQTLs which were not present in the normal unperturbed state. This also can partially explain
why we failed to identify AD-specific QTLs.
Together, these plans may deepen our understanding on how genetic controls of the human
protein level.

7.2 Future of AD genetics studies
Multi-omics genetic studies for AD would pave the way to develop truly effective treatment.
Instead of devoting a large proportion of time and money on the conventional Amyloid beta
focused studies, we can systematically dissect the AD pathogenesis and even the causal or driver
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gene. As the genome sequencing decreases, population-scale short-read DNA sequencing
projects have been initiated within last decade, such as Alzheimer Disease Sequencing Project
(ADSP) and Accelerating Medicines Partnership (AMP)-AD. Functional genomic technologies
on different molecular layers have also exploded through last decade. Technologies on bulklevel and single-cell/nuclei (spatial) transcriptome profiling, open chromatin accessibility,
DNA/RNA-methylation, histone modification, chromatin conformation, targeted and untargeted
metabolomics/lipidomics could complement proteomics, and facilitate to map the mechanisms of
AD risk loci and eventually to development of the precision medicine.
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Appendix A Supplementary information for
Chapter 6
TableA1 211 human phenotypes (disease/risk factor) used in this study [from Zheng et al 2020 but found in the
upgraded database of MRBase since January 2020]. Variable id represents latest phenotype ID from MR-Base and
IEU open-gwas project (after January 2020); trait represents name of phenotype GWAS; Sample size represents
total sample size of the phenotype GWAS; year represents year in which phenotype GWAS published; Category
represents phenotype category defined in house in 2021
id

trait

ieu-a975
ieu-a822
ieu-a1025
ieu-a1029
ieu-a16
ieu-a1050
ieu-a1049
ieu-a1051
ieu-a1052
ieu-a45
ieu-a816
ieu-a1057
ieu-a1004
ieu-a1081
ieu-a961
ieu-a1006
ieu-a1008
ieu-a1043

Paget's disease

Sample
size
3440

year

Category

2011

Disease

Pancreatic cancer

3835

2009

Cancer

Multiple sclerosis

38589

2013

Disease

Internalizing problems

4596

2014

Childhood intelligence

12441

2014

Ferritin

23986

2014

Iron

23986

2014

Transferrin Saturation

23986

2014

Transferrin

23986

2014

Anorexia nervosa

17767

2014

4881

2013

Neurologi
cal
Personalit
y trait
Blood
trait
Blood
trait
Blood
trait
Blood
trait
Neurologi
cal
Cancer

Gallbladder cancer

907

2012

Cancer

Age at menopause

69360

2015

IgA nephropathy

5957

2010

Cigarettes smoked per day

68028

2010

Mean platelet volume

66867

2011

Platelet count

66867

2011

Amygdala volume

30717

2015

Biological
trait
Biological
trait
Personalit
y trait
Blood
trait
Blood
trait
Biological
trait

Neuroblastoma
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ieu-a1046
ieu-a1042
ieu-a1045
ieu-a1044
ieu-a1047
ieu-a1048
ieu-a1041
ieu-a815
ieu-a1112
ieu-a1055
ieu-a297
ieu-a970
ieu-a12
ieu-a294
ieu-a999
ieu-a23
ieu-a1111
ieu-a1110
ieu-a1109
ieu-a1108
ieu-a1005
ieu-a1128
ieu-a1127
ieu-a1126
ukb-a426
ukb-a423
ukb-a424
ukb-a-

Pallidum volume

30717

2015

Nucleus accumbens volume

30717

2015

Hippocampus volume

30717

2015

Caudate volume

30717

2015

Putamen volume

30717

2015

Thalamus volume

30717

2015

Intracranial volume

30717

2015

Systemic lupus erythematosus

3094

2008

Biological
trait
Biological
trait
Biological
trait
Biological
trait
Biological
trait
Biological
trait
Biological
trait
Disease

Primary sclerosing cholangitis

14890

2017

Disease

110347

2013

Alzheimer's disease

54162

2013

Ulcerative colitis

47745

2015

Biological
trait
Neurologi
cal
Disease

Crohn's disease

51874

2015

Disease

Inflammatory bowel disease

65642

2015

Disease

Body fat

100716

2016

Type 2 diabetes

110452

2014

Biological
trait
Disease

Small vessel disease

20675

2016

Disease

Large vessel disease

21143

2016

Disease

Cardioembolic stroke

21185

2016

Ischemic stroke

29633

2016

7667

2014

ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta
analysis)
ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta
analysis)
Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis)

127442

2017

Neurologi
cal
Neurologi
cal
Biological
trait
Cancer

175475

2017

Cancer

228951

2017

Cancer

Eye problems/disorders: Cataract

108817

2017

Disease

Eye problems/disorders: Diabetes related eye disease

108817

2017

Disease

Eye problems/disorders: Glaucoma

108817

2017

Disease

Eye problems/disorders: Injury or trauma resulting in loss of vision

108817

2017

Disease

Urate

Percent emphysema
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425
ukb-a363
ukb-a367
ukb-a500
ukb-a337
ukb-a336
ukb-a332
ukb-a360
ukb-a359
ukb-a257
ukb-a334
ukb-a335
ukb-a333
ukb-a9
ukb-a438
ukb-a440
ukb-a441
ukb-a439
ukb-a308
ukb-a248
ukb-a249
ukb-a436
ukb-a25
ukb-a59
ukb-a58
ukb-a57
ukb-a56
ukb-a88

Pulse rate

110153

2017

Happiness

110935

2017

Heel bone mineral density (BMD) T-score automated

194398

2017

Forced expiratory volume in 1-second (FEV1)

307638

2017

Forced vital capacity (FVC)

307638

2017

31762

2017

Systolic blood pressure automated reading

317754

2017

Diastolic blood pressure automated reading

317756

2017

Hearing difficulty/problems: Yes

323978

2017

Potassium in urine

326816

2017

Sodium in urine

326831

2017

Creatinine (enzymatic) in urine

327525

2017

Sleep duration

335410

2017

Fractured bone site(s): Ankle

335546

2017

Biological
trait
Personalit
y trait
Biological
trait
Biological
trait
Biological
trait
Biological
trait
Biological
trait
Biological
trait
Biological
trait
Biological
trait
Biological
trait
Biological
trait
Biological
trait
Other

Fractured bone site(s): Arm

335546

2017

Other

Fractured bone site(s): Other bones

335546

2017

Other

Fractured bone site(s): Wrist

335546

2017

Other

Fractured/broken bones in last 5 years

335587

2017

Other

Body mass index (BMI)

336107

2017

Weight

336227

2017

Vascular/heart problems diagnosed by doctor: Angina

336683

2017

Biological
trait
Biological
trait
Disease

Alcohol intake frequency.

336965

2017

Cancer code self-reported: basal cell carcinoma

337159

2017

Personalit
y trait
Cancer

Cancer code self-reported: malignant melanoma

337159

2017

Cancer

Cancer code self-reported: prostate cancer

337159

2017

Cancer

Cancer code self-reported: small intestine/small bowel cancer

337159

2017

Cancer

Non-cancer illness code self-reported: ankylosing spondylitis

337159

2017

Disease

Fracture resulting from simple fall
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ukb-a82
ukb-a113
ukb-a66
ukb-a73
ukb-a84
ukb-a67
ukb-a65
ukb-a81
ukb-a102
ukb-a68
ukb-a95
ukb-a70
ukb-a107
ukb-a94
ukb-a109
ukb-a108
ukb-a61
ukb-a76
ukb-a114
ukb-a98
ukb-a77
ukb-a89
ukb-a86
ukb-a72
ukb-a83
ukb-a78
ukb-a96
ukb-a-

Non-cancer illness code self-reported: anxiety/panic attacks

337159

2017

Non-cancer illness code self-reported: arthritis (nos)

337159

2017

Neurologi
cal
Diseae

Non-cancer illness code self-reported: asthma

337159

2017

Disease

Non-cancer illness code self-reported: bladder problem (not cancer)

337159

2017

Disease

Non-cancer illness code self-reported: bone disorder

337159

2017

Disease

Non-cancer illness code self-reported: chronic obstructive airways
disease/copd
Non-cancer illness code self-reported: deep venous thrombosis (dvt)

337159

2017

Disease

337159

2017

Disease

Non-cancer illness code self-reported: depression

337159

2017

Non-cancer illness code self-reported: diverticular
disease/diverticulitis
Non-cancer illness code self-reported: emphysema/chronic bronchitis

337159

2017

Neurologi
cal
Disease

337159

2017

Disease

Non-cancer illness code self-reported: enlarged prostate

337159

2017

Non-cancer illness code self-reported: gastro-oesophageal reflux
(gord) / gastric reflux
Non-cancer illness code self-reported: gout

337159

2017

Biological
trait
Disease

337159

2017

Disease

Non-cancer illness code self-reported: hayfever/allergic rhinitis

337159

2017

Disease

Non-cancer illness code self-reported: hiatus hernia

337159

2017

Disease

Non-cancer illness code self-reported: high cholesterol

337159

2017

Non-cancer illness code self-reported: hypertension

337159

2017

Non-cancer illness code self-reported: hyperthyroidism/thyrotoxicosis

337159

2017

Blood
trait
Blood
trait
Disease

Non-cancer illness code self-reported: hypertrophic cardiomyopathy
(hcm / hocm)
Non-cancer illness code self-reported: hypopituitarism

337159

2017

Disease

337159

2017

Disease

Non-cancer illness code self-reported: hypothyroidism/myxoedema

337159

2017

Disease

Non-cancer illness code self-reported: iron deficiency anaemia

337159

2017

Disease

Non-cancer illness code self-reported: joint disorder

337159

2017

Disease

Non-cancer illness code self-reported: kidney stone/ureter
stone/bladder stone
Non-cancer illness code self-reported: mania/bipolar disorder/manic
depression
Non-cancer illness code self-reported: migraine

337159

2017

Disease

337159

2017

337159

2017

Non-cancer illness code self-reported: muscle or soft tissue injuries

337159

2017

Neurologi
cal
Neurologi
cal
Disease

Non-cancer illness code self-reported: osteoarthritis

337159

2017

Disease
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106
ukb-a87
ukb-a90
ukb-a111
ukb-a112
ukb-a100
ukb-a64
ukb-a80
ukb-a69
ukb-a91
ukb-a92
ukb-a115
ukb-a517
ukb-a519
ukb-a520
ukb-a521
ukb-a522
ukb-a527
ukb-a528
ukb-a529
ukb-a535
ukb-a536
ukb-a537
ukb-a538
ukb-a539
ukb-a541
ukb-a544
ukb-a547

Non-cancer illness code self-reported: osteoporosis

337159

2017

Disease

Non-cancer illness code self-reported: pernicious anaemia

337159

2017

Non-cancer illness code self-reported: pneumothorax

337159

2017

Blood
trait
Disease

Non-cancer illness code self-reported: polio / poliomyelitis

337159

2017

Disease

Non-cancer illness code self-reported: psoriasis

337159

2017

Disease

Non-cancer illness code self-reported: pulmonary embolism +/- dvt

337159

2017

Disease

Non-cancer illness code self-reported: retinal detachment

337159

2017

Disease

Non-cancer illness code self-reported: sleep apnoea

337159

2017

Disease

Non-cancer illness code self-reported: uterine fibroids

337159

2017

Disease

Non-cancer illness code self-reported: vaginal prolapse/uterine
prolapse
Non-cancer illness code self-reported: vitiligo

337159

2017

Disease

337159

2017

Disease

Diagnoses - main ICD10: B37 Candidiasis

337199

2017

Disease

Diagnoses - main ICD10: C50 Malignant neoplasm of breast

337199

2017

Cancer

Diagnoses - main ICD10: C61 Malignant neoplasm of prostate

337199

2017

Cancer

Diagnoses - main ICD10: D12 Benign neoplasm of colon rectum
anus and anal canal
Diagnoses - main ICD10: D25 Leiomyoma of uterus

337199

2017

Cancer

337199

2017

Cancer

Diagnoses - main ICD10: G47 Sleep disorders

337199

2017

Disease

Diagnoses - main ICD10: G56 Mononeuropathies of upper limb

337199

2017

Diagnoses - main ICD10: H25 Senile cataract

337199

2017

Neurologi
cal
Disease

Diagnoses - main ICD10: I30 Acute pericarditis

337199

2017

Disease

Diagnoses - main ICD10: I48 Atrial fibrillation and flutter

337199

2017

Disease

Diagnoses - main ICD10: I80 Phlebitis and thrombophlebitis

337199

2017

Disease

Diagnoses - main ICD10: I83 Varicose veins of lower extremities

337199

2017

Disease

Diagnoses - main ICD10: I84 Haemorrhoids

337199

2017

Disease

Diagnoses - main ICD10: J33 Nasal polyp

337199

2017

Disease

Diagnoses - main ICD10: K20 Oesophagitis

337199

2017

Disease

Diagnoses - main ICD10: K29 Gastritis and duodenitis

337199

2017

Disease
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ukb-a548
ukb-a549
ukb-a550
ukb-a551
ukb-a555
ukb-a556
ukb-a559
ukb-a560
ukb-a562
ukb-a563
ukb-a566
ukb-a569
ukb-a572
ukb-a574
ukb-a576
ukb-a577
ukb-a578
ukb-a580
ukb-a581
ukb-a582
ukb-a583
ukb-a584
ukb-a586
ukb-a587
ukb-a591
ukb-a592
ukb-a594
ukb-a-

Diagnoses - main ICD10: K35 Acute appendicitis

337199

2017

Disease

Diagnoses - main ICD10: K40 Inguinal hernia

337199

2017

Disease

Diagnoses - main ICD10: K43 Ventral hernia

337199

2017

Disease

Diagnoses - main ICD10: K44 Diaphragmatic hernia

337199

2017

Disease

Diagnoses - main ICD10: K57 Diverticular disease of intestine

337199

2017

Disease

Diagnoses - main ICD10: K60 Fissure and fistula of anal and rectal
regions
Diagnoses - main ICD10: K80 Cholelithiasis

337199

2017

Disease

337199

2017

Disease

Diagnoses - main ICD10: L03 Cellulitis

337199

2017

Disease

Diagnoses - main ICD10: M16 Coxarthrosis [arthrosis of hip]

337199

2017

Disease

Diagnoses - main ICD10: M17 Gonarthrosis [arthrosis of knee]

337199

2017

Disease

Diagnoses - main ICD10: M23 Internal derangement of knee

337199

2017

Disease

Diagnoses - main ICD10: M54 Dorsalgia

337199

2017

Disease

Diagnoses - main ICD10: M72 Fibroblastic disorders

337199

2017

Disease

Diagnoses - main ICD10: N20 Calculus of kidney and ureter

337199

2017

Disease

Diagnoses - main ICD10: N40 Hyperplasia of prostate

337199

2017

Disease

Diagnoses - main ICD10: N81 Female genital prolapse

337199

2017

Disease

Diagnoses - main ICD10: N92 Excessive frequent and irregular
menstruation
Diagnoses - main ICD10: R04 Haemorrhage from respiratory
passages
Diagnoses - main ICD10: R07 Pain in throat and chest

337199

2017

Disease

337199

2017

Disease

337199

2017

Disease

Diagnoses - main ICD10: R10 Abdominal and pelvic pain

337199

2017

Disease

Diagnoses - main ICD10: R11 Nausea and vomiting

337199

2017

Other

Diagnoses - main ICD10: R14 Flatulence and related conditions

337199

2017

Other

Diagnoses - main ICD10: R35 Polyuria

337199

2017

Disease

Diagnoses - main ICD10: R55 Syncope and collapse

337199

2017

Disease

Diagnoses - main ICD10: S66 Injury of muscle and tendon at wrist
and hand level
Diagnoses - main ICD10: S76 Injury of muscle and tendon at hip and
thigh level
Diagnoses - main ICD10: Z09 Follow-up examination after treatment
for conditions other than malignant neoplasms
Underlying (primary) cause of death: ICD10: E85.4 Organ-limited

337199

2017

Disease

337199

2017

Disease

337199

2017

Disease

7637

2017

Disease
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357
ukb-a258
ieu-a798
ieu-a-7
ieu-a833
ieu-a1000
ieu-a1007
ieu-a1009
ieu-a996
ieu-a1102
ieu-a1105
ieu-a1106
ieu-a1095
ieu-a1122
ieu-a1124
ieu-a1123
ieu-a1125
ieu-a1121
ieu-a1120
ieu-a837
ieu-a812
ieu-a801
ieu-a802
ieu-a803
ieu-a805
ieu-a983
ieu-a1097
ieu-a1107
ieu-a-

amyloidosis
Cough on most days

83529

2017

Other

Myocardial infarction

171875

2015

Disease

Coronary heart disease
Rheumatoid arthritis

184305
80799

2015
2014

Disease
Disease

Depressive symptoms

161460

2016

Neuroticism

170911

2016

Subjective well being

298420

2016

40835

2014

Neurologi
cal
Personalit
y trait
Neurologi
cal
Disease

Chronic kidney disease

117165

2015

Disease

Serum creatinine (eGFRcrea)

133814

2015

Serum cystatin C (eGFRcys)

33152

2015

182416

2014

Low grade serous ovarian cancer

41953

2017

Blood
trait
Blood
trait
Biological
trait
Cancer

Clear cell ovarian cancer

42307

2017

Cancer

Invasive mucinous ovarian cancer

42358

2017

Cancer

Endometrioid ovarian cancer

43751

2017

Cancer

High grade serous ovarian cancer

53978

2017

Cancer

Ovarian cancer

66450

2017

Cancer

Years of schooling

101069

2013

Parkinson's disease

5691

2009

Bipolar disorder

16731

2011

Autism

29415

2013

PGC cross-disorder traits

61220

2013

Major depressive disorder

18759

2013

788

2010

Biological
trait
Neurologi
cal
Neurologi
cal
Neurologi
cal
Neurologi
cal
Neurologi
cal
Disease

Microalbuminuria

54116

2015

Urinary albumin-to-creatinine ratio

54450

2015

Celiac disease

24269

2011

Eczema

Age at menarche

Hirschsprung's disease
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Biological
trait
Biological
trait
Disease

1058
ieu-a990
ieu-a967
ieu-a965
ieu-a966
ieu-a300
ieu-a302
ieu-a299
ieu-a301
ieu-a89
ieu-a1171
ieu-a1169
ieu-a1170
ieu-a982
ieu-a980
ieu-a977
ieu-a113
ieu-a117
ieu-a114
ieu-a116
ieu-a115
ieu-a274
ieu-a271
ieu-a275
ieu-a272
ieu-a273
ieu-a270
ieu-a29

Bulimia nervosa

2442

2013

Squamous cell lung cancer

18313

2014

Neurologi
cal
Cancer

Lung adenocarcinoma

18336

2014

Cancer

Lung cancer

27209

2014

Cancer

LDL cholesterol

173082

2013

Triglycerides

177861

2013

HDL cholesterol

187167

2013

Total cholesterol

187365

2013

Height

253288

2014

Knee osteoarthritis

11655

2012

Blood
trait
Blood
trait
Blood
trait
Blood
trait
Biological
trait
Disease

Hip osteoarthritis

14275

2012

Disease

Knee and hip osteoarthritis

14507

2012

Disease

Lumbar spine bone mineral density

28498

2015

Femoral neck bone mineral density

32735

2015

8143

2015

Neo-agreeableness

17375

2012

Neo-openness to experience

17375

2012

Neo-conscientiousness

17375

2012

Neo-neuroticism

17375

2012

Neo-extraversion

17375

2012

Packed cell volume

63511

2012

Mean cell haemoglobin

64731

2012

Red blood cell count

66214

2012

Mean cell haemoglobin concentration

67852

2012

Mean cell volume

69335

2012

Haemoglobin concentration

71861

2012

Birth length

28459

2015

Biological
trait
Biological
trait
Biological
trait
Personalit
y trait
Personalit
y trait
Personalit
y trait
Personalit
y trait
Personalit
y trait
Blood
trait
Blood
trait
Blood
trait
Blood
trait
Blood
trait
Blood
trait
Biological
trait

Forearm bone mineral density
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Education:
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2015-present
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Washington University School of Medicine in St. Louis, St. Louis, USA

2013-2014

Bachelor of Science in Biological Sciences
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2009-2013

Research Experience:
Graduate
student

Lab of Dr. Carlos Cruchaga, Washington
University School of Medicine
•

•

•

Graduate
student until

2018-present

Identified protein-level quantitative loci
(pQTLs) in cerebrospinal fluid, plasma, and
brain tissues from a cohort of Alzheimer disease
(AD) patients and cognitive healthy controls.
(Yang et al 2021 Nature Neuro)
Inferred causal proteins with >200 traits with
Mendelian randomization and colocalization.
(Yang et al 2021 Nature Neuro, Yang et al 2021
under review)
Discovered and replicated potential biomarkers
in cerebrospinal fluid and plasma that
differentially expressed between AD patients
and cognitive healthy controls. (Sung et al 2021
submitted)

Labs of Drs. Joe Dougherty and Don Conrad ,
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2016-2018

Don Conrad
left WashU to
OHSU

Washington University School of Medicine
•

•

•

•

Programmer
and Master’s
thesis student

Constructed the plasmid DNA library for
sgRNAs targeting the autism risk genes for a
CRISPRi screen with single-cell RNA-seq
readouts.
Analyzed datasets from in-house and original
Perturb-seq using regression-based approach and
validated using pseudo-bulk strategy.
Assembled the plasmid DNA construct of a
dual-fluorescent reporter for genetic screening
the regulators of Aqp4 stop codon readthrough.
Identified motifs, position weight matrix, RNA
structure on stop-codon readthrough, identified
by cell-type specific ribosome footprint profiling
technique (prepared revision materials for
Sapkota et al 2019).

Lab of Dr. Joe Dougherty, Washington
University School of Medicine
•

•

•

2014-2015

Developed pipelines mapping ribosome
profiling reads to mouse genome and
transcriptome. (Dalal, Yang et al 2017)
Successfully searched stop codon in the 3’Untranslated Region of mouse cDNA sequence
and rigorously defined stop codon readthrough
per transcript. (Dalal, Yang et al 2017)
Tested Hypotheses that whether neural
depolarization would regulate stop codon
readthrough rate, and translation efficiency.
(Dalal, Yang et al 2017)
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